{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1136,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":1136,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"7437e4e67cc8","filters":{"topic":"Chronic Myeloid Leukemia Treatments"}},"results":[{"id":"W2028959752","doi":"10.1056/nejmoa022457","title":"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","year":2003,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3565,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Imatinib; Cytarabine; Internal medicine; Gastroenterology; Myeloid leukemia; Imatinib mesylate; Confidence interval; Alpha interferon; Philadelphia chromosome; Immunology; Interferon; Oncology; Biology; Chromosomal translocation","authors":[{"name":"Stephen G. O’Brien","is_ca":false},{"name":"François Guilhot","is_ca":false},{"name":"Richard A. Larson","is_ca":false},{"name":"Insa Gathmann","is_ca":false},{"name":"Michele Baccarani","is_ca":false},{"name":"Francisco Cervantes","is_ca":false},{"name":"Jan J. Cornelissen","is_ca":false},{"name":"Thomas Fischer","is_ca":false},{"name":"Andreas Hochhaus","is_ca":false},{"name":"Timothy P. Hughes","is_ca":false},{"name":"Klaus Lechner","is_ca":false},{"name":"Johan Lanng Nielsen","is_ca":false},{"name":"Philippe Rousselot","is_ca":false},{"name":"Josy Reiffers","is_ca":false},{"name":"Giuseppe Saglio","is_ca":false},{"name":"John D. Shepherd","is_ca":true},{"name":"Bengt Simonsson","is_ca":false},{"name":"Aloïs Gratwohl","is_ca":false},{"name":"John M. Goldman","is_ca":false},{"name":"Hagop M. Kantarjian","is_ca":false},{"name":"Kerry Taylor","is_ca":false},{"name":"Gregor Verhoef","is_ca":false},{"name":"Ann E. Bolton","is_ca":false},{"name":"Renaud Capdeville","is_ca":false},{"name":"Brian Druker","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0192848738368445,"gpt":0.2947119224179476,"spread":0.2754270485811031,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00152125,0.0002207804,0.0005367192,0.000198564,0.0001319831,0.0002606619,0.0001932425,0.0003316774,0.002515976],"category_scores_gemma":[0.002385252,0.00008222346,0.0005848834,0.0001809289,0.0002550414,0.0002234992,0.0001987252,0.0006591411,0.000187216],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003864981,"about_ca_system_score_gemma":0.0003102335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002326507,"about_ca_topic_score_gemma":0.0007008173,"domain_scores_codex":[0.9991975,0.0005416565,0.00007279297,0.00006846972,0.00007475247,0.00004472524],"domain_scores_gemma":[0.9982029,0.0009991443,0.0004272356,0.00004583977,0.00004812703,0.0002768415],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6482722,0.004575364,0.04174788,0.001202714,0.001509041,0.0002341045,0.0001924384,0.002571399,0.009657812,0.0004440435,0.0008087169,0.2887843],"study_design_scores_gemma":[0.2016456,0.5838071,0.1867424,0.00059072,0.002606654,0.001825711,0.0001758964,0.00629053,0.007056121,0.0008212973,0.008374469,0.00006348537],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993586,0.005111957,0.0002551059,0.000192926,0.00008844099,0.0001194091,0.0000462181,0.000007670514,0.0005921734],"genre_scores_gemma":[0.9982188,0.0009770478,0.0003167731,0.00008148451,0.00006919207,0.00006588831,0.00007270643,0.000001261122,0.0001967866],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002515976,"threshold_uncertainty_score":0.008416772,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2107268345","doi":"10.1056/nejmoa062867","title":"Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia","year":2006,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3481,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver General Hospital","funders":"Celgene; Pfizer; Kementerian Pendidikan Nasional; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Imatinib; Internal medicine; Cytarabine; Myeloid leukemia; Adverse effect; Imatinib mesylate; Philadelphia chromosome; Alpha interferon; Gastroenterology; Oncology; Surgery; Immunology; Interferon; Chromosomal translocation","authors":[{"name":"Brian Druker","is_ca":false},{"name":"François Guilhot","is_ca":false},{"name":"Stephen G. O’Brien","is_ca":false},{"name":"Insa Gathmann","is_ca":false},{"name":"Hagop M. Kantarjian","is_ca":false},{"name":"Norbert Gattermann","is_ca":false},{"name":"Michael W. Deininger","is_ca":false},{"name":"Richard T. Silver","is_ca":false},{"name":"John M. Goldman","is_ca":false},{"name":"Richard M. Stone","is_ca":false},{"name":"Francisco Cervantes","is_ca":false},{"name":"Andreas Hochhaus","is_ca":false},{"name":"Bayard L. Powell","is_ca":false},{"name":"Janice Gabrilove","is_ca":false},{"name":"Philippe Rousselot","is_ca":false},{"name":"Josy Reiffers","is_ca":false},{"name":"Jan J. Cornelissen","is_ca":false},{"name":"Timothy P. Hughes","is_ca":false},{"name":"Hermine Agis","is_ca":false},{"name":"Thomas Fischer","is_ca":false},{"name":"Gregor Verhoef","is_ca":false},{"name":"John D. Shepherd","is_ca":true},{"name":"Giuseppe Saglio","is_ca":false},{"name":"Aloïs Gratwohl","is_ca":false},{"name":"Johan Lanng Nielsen","is_ca":false},{"name":"Jerald P. Radich","is_ca":false},{"name":"Bengt Simonsson","is_ca":false},{"name":"Kerry Taylor","is_ca":false},{"name":"Michele Baccarani","is_ca":false},{"name":"Charlene So","is_ca":false},{"name":"Laurie Letvak","is_ca":false},{"name":"Richard A. Larson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01252982675583111,"gpt":0.2622417208740349,"spread":0.2497118941182038,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006381366,0.0002366292,0.0004568737,0.0004812009,0.0006714656,0.0005419787,0.0002501651,0.0007065665,0.001498871],"category_scores_gemma":[0.002260127,0.0001604975,0.0005362519,0.0004351284,0.0002334969,0.0004925447,0.0003204892,0.0006458333,0.0003430983],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004689973,"about_ca_system_score_gemma":0.0003071908,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003453243,"about_ca_topic_score_gemma":0.002891198,"domain_scores_codex":[0.9996287,0.00007331587,0.00003556604,0.00007583552,0.00007112154,0.0001154903],"domain_scores_gemma":[0.9986002,0.0002119786,0.0004800865,0.00008510637,0.0001925081,0.0004301707],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009628526,0.0001572375,0.9939439,0.000009466217,0.00007579863,0.000383145,0.0001134907,0.0001270028,0.0003438976,0.00001265693,0.0002033183,0.003667234],"study_design_scores_gemma":[0.00008393769,0.001245772,0.9967821,0.00000805962,0.0001066373,0.0006928816,0.00008735425,0.0002936516,0.0001384471,0.00002137501,0.000529681,0.00001007639],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9989309,0.0002656311,0.00006075294,0.00005896587,0.000008523647,0.00001400037,0.0002902814,0.000004024309,0.0003669063],"genre_scores_gemma":[0.9992291,0.00004811015,0.00003458968,0.0000508917,0.00001051516,0.00001116678,0.0004260275,6.764119e-7,0.0001888645],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003453243,"threshold_uncertainty_score":0.006866336,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1968747503","doi":"10.1182/blood-2013-05-501569","title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","year":2013,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1989,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institute for Health and Care Research","keywords":"Medicine; Myeloid leukemia; Internal medicine; Intensive care medicine","authors":[{"name":"Michele Baccarani","is_ca":false},{"name":"Michael Deininger","is_ca":false},{"name":"Gianantonio Rosti","is_ca":false},{"name":"Andreas Hochhaus","is_ca":false},{"name":"Simona Soverini","is_ca":false},{"name":"Jane F. Apperley","is_ca":false},{"name":"Francisco Cervantes","is_ca":false},{"name":"Richard E. Clark","is_ca":false},{"name":"Jörge E. Cortes","is_ca":false},{"name":"François Guilhot","is_ca":false},{"name":"Henrik Hjorth‐Hansen","is_ca":false},{"name":"Timothy P. Hughes","is_ca":false},{"name":"Hagop M. Kantarjian","is_ca":false},{"name":"Dong‐Wook Kim","is_ca":false},{"name":"Richard A. Larson","is_ca":false},{"name":"Jeffrey H. Lipton","is_ca":true},{"name":"François-Xavier Mahon","is_ca":false},{"name":"Giovanni Martinelli","is_ca":false},{"name":"Jiřı́ Mayer","is_ca":false},{"name":"Martin Müller","is_ca":false},{"name":"Dietger Niederwieser","is_ca":false},{"name":"Fabrizio Pane","is_ca":false},{"name":"Jerald P. Radich","is_ca":false},{"name":"Philippe Rousselot","is_ca":false},{"name":"Giuseppe Saglio","is_ca":false},{"name":"Susanne Saußele","is_ca":false},{"name":"Charles A. Schiffer","is_ca":false},{"name":"Richard T. Silver","is_ca":false},{"name":"Bengt Simonsson","is_ca":false},{"name":"Juan-Luis Steegmann","is_ca":false},{"name":"John M. Goldman","is_ca":false},{"name":"Rüdiger Hehlmann","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05498044835877869,"gpt":0.3203154554899036,"spread":0.265335007131125,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006718352,0.0007544603,0.001048441,0.002481916,0.0007476339,0.002515036,0.002688772,0.003333721,0.02406065],"category_scores_gemma":[0.01174762,0.0003724724,0.001703068,0.003085915,0.0008109756,0.001483032,0.002186243,0.005223239,0.01966902],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00474953,"about_ca_system_score_gemma":0.01077958,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01450011,"about_ca_topic_score_gemma":0.0282152,"domain_scores_codex":[0.9950787,0.001493342,0.0009971537,0.0001941299,0.001858441,0.0003781669],"domain_scores_gemma":[0.9932361,0.0008250482,0.001196213,0.0002447134,0.003721544,0.0007763432],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007884974,0.0001177029,0.0007559378,0.0006368719,0.00002457294,0.00007634752,0.00004635368,0.0003815232,0.0002908322,0.004008112,0.8020382,0.1915447],"study_design_scores_gemma":[0.0000766926,0.00002926597,0.001858084,0.001241119,0.00002544641,0.0001926041,0.00003280188,0.00009907973,0.0001643141,0.001768872,0.9944981,0.0000135201],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"review","genre_scores_codex":[0.004909137,0.1805251,0.03002085,0.3056868,0.02437248,0.005264533,0.03663127,0.002364077,0.4102257],"genre_scores_gemma":[0.02943774,0.1908821,0.141953,0.2427913,0.009645035,0.008218578,0.09220972,0.001583166,0.2832795],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.02406065,"threshold_uncertainty_score":0.08049083,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3009751715","doi":"10.1038/s41375-020-0776-2","title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","year":2020,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1510,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"Daiichi Sankyo Europe; Scheme for Promotion of Academic and Research Collaboration; Sun Pharma; Servier; Astellas Pharma; Incyte; Italfarmaco; Seagen; Agios Pharmaceuticals; Astex Pharmaceuticals; Celgene; Daiichi-Sankyo; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Gilead Sciences; Ariad Pharmaceuticals; Amgen; Pfizer; Ascentage Pharma","keywords":"Medicine; Dasatinib; Nilotinib; Bosutinib; Discontinuation; Imatinib; Myeloid leukemia; Tyrosine-kinase inhibitor; Internal medicine; Oncology; Intensive care medicine","authors":[{"name":"Andreas Hochhaus","is_ca":false},{"name":"Michele Baccarani","is_ca":false},{"name":"Richard T. Silver","is_ca":false},{"name":"CA Schiffer","is_ca":false},{"name":"Jane F. Apperley","is_ca":false},{"name":"Francisco Cervantes","is_ca":false},{"name":"R E Clark","is_ca":false},{"name":"J. E. Cortes","is_ca":false},{"name":"Michael W. Deininger","is_ca":false},{"name":"François Guilhot","is_ca":false},{"name":"Henrik Hjorth‐Hansen","is_ca":false},{"name":"Timothy P. Hughes","is_ca":false},{"name":"J. Janssen","is_ca":false},{"name":"Hagop M. Kantarjian","is_ca":false},{"name":"D. W. Kim","is_ca":false},{"name":"Richard A. Larson","is_ca":false},{"name":"J. H. Lipton","is_ca":true},{"name":"F.-X. Mahon","is_ca":false},{"name":"Jiří Mayer","is_ca":false},{"name":"Franck E. Nicolini","is_ca":false},{"name":"D Niederwieser","is_ca":false},{"name":"Fabrizio Pane","is_ca":false},{"name":"Jerald P. Radich","is_ca":false},{"name":"Delphine Réa","is_ca":false},{"name":"Johan Richter","is_ca":false},{"name":"G Rosti","is_ca":false},{"name":"Philipe Rousselot","is_ca":false},{"name":"Giuseppe Saglio","is_ca":false},{"name":"Susanne Saußele","is_ca":false},{"name":"Simona Soverini","is_ca":false},{"name":"J. L. Steegmann","is_ca":false},{"name":"Anna Turkina","is_ca":false},{"name":"Andrey Zaritskey","is_ca":false},{"name":"R. Hehlmann","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04811984751068918,"gpt":0.3335786658783663,"spread":0.2854588183676771,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001671417,0.001074119,0.001367766,0.003856944,0.0003742301,0.001429713,0.001969991,0.001923948,0.02379],"category_scores_gemma":[0.001979389,0.000296305,0.001548305,0.003634206,0.0003388823,0.001332544,0.001070554,0.001969267,0.01509197],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001496943,"about_ca_system_score_gemma":0.004075973,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002930646,"about_ca_topic_score_gemma":0.004611511,"domain_scores_codex":[0.9991824,0.000216176,0.00015395,0.00005848378,0.0003191217,0.00006995161],"domain_scores_gemma":[0.9992334,0.0002053256,0.0001719151,0.00002152507,0.0002985866,0.00006925183],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008780618,0.00005604856,0.00007576928,0.015665,0.00007158227,0.00007445401,0.00003340776,0.0001760234,0.00038697,0.004435709,0.3031957,0.6757416],"study_design_scores_gemma":[0.00002603925,0.00001884002,0.000162609,0.005677086,0.00004984889,0.0001135439,0.000009826609,0.00001732143,0.00004312519,0.0007505272,0.9931267,0.000004431021],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001813081,0.962051,0.0006075138,0.006545053,0.003228905,0.0002980669,0.001417792,0.0001375383,0.02553282],"genre_scores_gemma":[0.001030803,0.9720477,0.002715148,0.007388079,0.0006667606,0.0002992099,0.002568767,0.00003297607,0.01325053],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02379,"threshold_uncertainty_score":0.07958549,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2012962381","doi":"10.1056/nejmoa040258","title":"Granulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML","year":2004,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1489,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Chronic myelogenous leukemia; Stem cell; Blast Crisis; Haematopoiesis; Progenitor cell; Medicine; Cancer research; Leukemia; Immunology; Cell biology; Biology","authors":[{"name":"Catriona Jamieson","is_ca":false},{"name":"Laurie Ailles","is_ca":false},{"name":"Scott J. Dylla","is_ca":false},{"name":"Manja Muijtjens","is_ca":false},{"name":"Carol D. Jones","is_ca":false},{"name":"James L. Zehnder","is_ca":false},{"name":"Jason Gotlib","is_ca":false},{"name":"Kevin Li","is_ca":false},{"name":"Markus G. Manz","is_ca":false},{"name":"Armand Keating","is_ca":true},{"name":"Charles L. Sawyers","is_ca":false},{"name":"Irving L. Weissman","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01126369969363871,"gpt":0.2634698004514213,"spread":0.2522061007577825,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002010626,0.0002331445,0.0002358584,0.0006009314,0.000141275,0.0002535542,0.0001506569,0.0002283213,0.0008551251],"category_scores_gemma":[0.0001925625,0.00008285636,0.0000866043,0.0002893881,0.0001315333,0.0001201917,0.000275262,0.0002059903,0.0003263633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001525228,"about_ca_system_score_gemma":0.0001695181,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001271354,"about_ca_topic_score_gemma":0.0002150706,"domain_scores_codex":[0.9999431,0.00001140129,0.000007244412,0.00001075966,0.000018497,0.000008919527],"domain_scores_gemma":[0.9999381,0.00001579063,0.00001432757,0.000005727489,0.000008974611,0.00001715849],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.001619021,0.00009948951,0.05243917,0.0002112193,0.00001762214,0.002314437,0.0002942665,0.0003254297,0.9186504,0.0005990991,0.0002954078,0.0231345],"study_design_scores_gemma":[0.0004276726,0.002055564,0.1614812,0.0001609509,0.0002050206,0.02641862,0.0006291632,0.006283974,0.7782396,0.001908841,0.02216147,0.00002798908],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957371,0.00126605,0.001827828,0.00004616083,0.000005256974,0.0001175798,0.0002757063,0.00004049061,0.0006840028],"genre_scores_gemma":[0.9936711,0.0007458405,0.004172038,0.0000619223,0.000009023997,0.00009138747,0.000849154,0.000009872397,0.0003896886],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008551251,"threshold_uncertainty_score":0.002860665,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2148743957","doi":"10.1182/blood-2006-01-0092","title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","year":2006,"lang":"en","type":"review","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1202,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Fogarty International Center; European Commission","keywords":"Imatinib mesylate; Tyrosine kinase; Philadelphia chromosome; Fluorescence in situ hybridization; Imatinib; ABL; Myeloid leukemia; Cancer research; Medicine; breakpoint cluster region; Tyrosine-kinase inhibitor; Internal medicine; Oncology; Biology; Bioinformatics; Gene; Genetics; Cancer; Chromosomal translocation; Chromosome; Receptor","authors":[{"name":"Tim Hughes","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1864627210656154,"gpt":0.4071127916725872,"spread":0.2206500706069719,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002222518,0.0009776503,0.002520242,0.00302496,0.000284269,0.000959155,0.001794803,0.001422995,0.002559573],"category_scores_gemma":[0.002045876,0.0003539899,0.0006908834,0.004088963,0.0005379951,0.00166807,0.0004655236,0.001429121,0.002279624],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009026603,"about_ca_system_score_gemma":0.002370476,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002023772,"about_ca_topic_score_gemma":0.004330316,"domain_scores_codex":[0.9993339,0.000203993,0.0001681958,0.00006595984,0.0002020809,0.00002586204],"domain_scores_gemma":[0.9986738,0.0004992468,0.0002510416,0.00003291034,0.0004728613,0.00007013143],"domain_codex":null,"domain_gemma":"methods","domain_candidate":"methods","domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008499917,0.00006331952,0.0002148266,0.02216006,0.0001092574,0.0002452003,0.00006196561,0.0002715818,0.0007902216,0.00183274,0.05561458,0.9185513],"study_design_scores_gemma":[0.0000403102,0.0001034091,0.001206142,0.01091249,0.0002227174,0.001108625,0.00009542565,0.0001032578,0.0002387775,0.001334302,0.9846119,0.00002260195],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00008455956,0.9974877,0.0002131379,0.001189333,0.0003337637,0.00001835881,0.00003085216,0.00001173016,0.0006305529],"genre_scores_gemma":[0.0004135791,0.9971375,0.001161868,0.0006434372,0.0001566424,0.00003257317,0.00005454277,0.000002122792,0.0003976696],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9977775,"threshold_uncertainty_score":0.01175398,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2096336184","doi":"10.1200/jco.2008.21.2514","title":"Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":709,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Imatinib; Lymphoblastic Leukemia; Oncology; Internal medicine; Philadelphia chromosome; Leukemia; Chromosomal translocation; Genetics; Gene; Myeloid leukemia","authors":[{"name":"Kirk R. Schultz","is_ca":true},{"name":"W. Paul Bowman","is_ca":true},{"name":"Alexander Aledo","is_ca":true},{"name":"William B. Slayton","is_ca":true},{"name":"Harland N. Sather","is_ca":true},{"name":"Meenakshi Devidas","is_ca":true},{"name":"Chenguang Wang","is_ca":true},{"name":"Stella M. Davies","is_ca":true},{"name":"Paul S. Gaynon","is_ca":true},{"name":"Michael E. Trigg","is_ca":true},{"name":"Robert Rutledge","is_ca":true},{"name":"Laura Burden","is_ca":true},{"name":"Dean Jorstad","is_ca":true},{"name":"Andrew J. Carroll","is_ca":true},{"name":"Nyla A. Heerema","is_ca":true},{"name":"Naomi Winick","is_ca":true},{"name":"Michael J. Borowitz","is_ca":true},{"name":"Stephen P. Hunger","is_ca":true},{"name":"William L. Carroll","is_ca":true},{"name":"Bruce M. Camitta","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03415208848965093,"gpt":0.3877666745477761,"spread":0.3536145860581252,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001212524,0.000448475,0.0005313238,0.000343828,0.0003703312,0.0005763802,0.0002566157,0.0005615941,0.0007077388],"category_scores_gemma":[0.001074445,0.0001724025,0.000623225,0.000563558,0.0004391374,0.0003407802,0.0003414073,0.0006854518,0.0001078006],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007779673,"about_ca_system_score_gemma":0.0007785878,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002730974,"about_ca_topic_score_gemma":0.003496444,"domain_scores_codex":[0.9993953,0.0002367377,0.00003681509,0.0001321314,0.00009512995,0.0001040412],"domain_scores_gemma":[0.9989755,0.0001402446,0.0003875296,0.00007886645,0.00006054442,0.0003574481],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.005196335,0.0004950791,0.9857904,0.00003060637,0.0004493265,0.0004472458,0.0001568572,0.0002875931,0.001814985,0.00006398492,0.000426766,0.004840684],"study_design_scores_gemma":[0.0007120018,0.00293568,0.993606,0.00001136721,0.000247507,0.0008372467,0.00007511726,0.0001653197,0.0004319283,0.0000317221,0.000936257,0.00001002067],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9991855,0.0003042742,0.00002982082,0.00006249928,0.000004457445,0.00001401352,0.0001874019,0.000002220386,0.0002097291],"genre_scores_gemma":[0.9990848,0.0001995203,0.00008298879,0.00006393361,0.00001651206,0.00001705139,0.0004491842,0.000002343135,0.00008360747],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002730974,"threshold_uncertainty_score":0.006412506,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2080125373","doi":"10.1182/blood-2006-09-047266","title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":609,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dasatinib; Imatinib; Medicine; Myeloid leukemia; Internal medicine; Imatinib mesylate; Adverse effect; Nilotinib; Oncology; Pharmacology; Gastroenterology; Immunology","authors":[{"name":"Andreas Hochhaus","is_ca":false},{"name":"Hagop M. Kantarjian","is_ca":false},{"name":"Michele Baccarani","is_ca":false},{"name":"Jeffrey H. Lipton","is_ca":true},{"name":"Jane F. Apperley","is_ca":false},{"name":"Brian Druker","is_ca":false},{"name":"Thierry Façon","is_ca":false},{"name":"Stuart L. Goldberg","is_ca":false},{"name":"Francisco Cervantes","is_ca":false},{"name":"Dietger Niederwieser","is_ca":false},{"name":"Richard T. Silver","is_ca":false},{"name":"Richard M. Stone","is_ca":false},{"name":"Timothy P. Hughes","is_ca":false},{"name":"Martin C. Müller","is_ca":false},{"name":"Rana Ezzeddine","is_ca":false},{"name":"Athena Countouriotis","is_ca":false},{"name":"Neil P. Shah","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01723478757040318,"gpt":0.2844798465666158,"spread":0.2672450589962126,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030662,0.0002167889,0.0004289076,0.0001740476,0.000176485,0.0001651234,0.0001302653,0.0002136776,0.0008482331],"category_scores_gemma":[0.0005085381,0.00008521508,0.0002147163,0.0001700711,0.0001736699,0.0001191132,0.0001380641,0.0004328738,0.0002469137],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001923309,"about_ca_system_score_gemma":0.0001412929,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002146361,"about_ca_topic_score_gemma":0.0005897811,"domain_scores_codex":[0.9997912,0.00005542441,0.00002494755,0.00002256075,0.00004763297,0.00005825276],"domain_scores_gemma":[0.9997893,0.00005763732,0.00004976003,0.00002969044,0.00001762763,0.00005593961],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.009370841,0.002259004,0.02840853,0.0004901338,0.0002329173,0.003252761,0.0002614593,0.001049185,0.8634463,0.0001946508,0.001946697,0.08908749],"study_design_scores_gemma":[0.005038526,0.09919944,0.4091371,0.00004256075,0.0002803256,0.02503646,0.0002382452,0.002848872,0.4383839,0.0003086403,0.01942305,0.00006288716],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978309,0.0008124753,0.0002304565,0.00005307881,0.00001543608,0.00005055362,0.0001249055,0.00003150257,0.0008507902],"genre_scores_gemma":[0.9990541,0.0001982212,0.0001176879,0.00004725236,0.00001057397,0.00002201414,0.0002523467,0.00000384099,0.0002939092],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008482331,"threshold_uncertainty_score":0.002837598,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2528188718","doi":"10.1200/jco.2016.68.2914","title":"Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":494,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Saint-François d'Assise","funders":"","keywords":"Medicine; Discontinuation; Imatinib; Myeloid leukemia; Internal medicine; Surgery; Imatinib mesylate; Minimal residual disease; Population; Gastroenterology; Leukemia","authors":[{"name":"Gabriel Étienne","is_ca":true},{"name":"Joëlle Guilhot","is_ca":true},{"name":"Delphine Réa","is_ca":true},{"name":"Françoise Rigal‐Huguet","is_ca":true},{"name":"Franck E. Nicolini","is_ca":true},{"name":"Aude Charbonnier","is_ca":true},{"name":"Agnès Guerci‐Bresler","is_ca":true},{"name":"Laurence Legros","is_ca":true},{"name":"Bruno Varet","is_ca":true},{"name":"Martine Gardembas","is_ca":true},{"name":"Viviane Dubruille","is_ca":true},{"name":"Michel Tulliez","is_ca":true},{"name":"Marie‐Pierre Noël","is_ca":true},{"name":"Jean‐Christophe Ianotto","is_ca":true},{"name":"Bruno Villemagne","is_ca":true},{"name":"Martin Carré","is_ca":true},{"name":"François Guilhot","is_ca":true},{"name":"Philippe Rousselot","is_ca":true},{"name":"François‐Xavier Mahon","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0484770343475114,"gpt":0.3846886422397793,"spread":0.3362116078922679,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002372768,0.0003858875,0.000599023,0.0003040956,0.0003891701,0.0005762368,0.0002463528,0.0005765642,0.0005270281],"category_scores_gemma":[0.002772491,0.0002005137,0.0006207571,0.0002884733,0.0003430149,0.0004494767,0.0003684932,0.0004535215,0.000144209],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005072788,"about_ca_system_score_gemma":0.0003547259,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001270251,"about_ca_topic_score_gemma":0.001735282,"domain_scores_codex":[0.9991255,0.0004238242,0.00006417041,0.0001305889,0.0001196133,0.0001362694],"domain_scores_gemma":[0.9979943,0.0005383094,0.000841435,0.0001546959,0.0001422291,0.0003289066],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006136653,0.0001331718,0.98272,0.00003470486,0.0002911422,0.0002421158,0.0001071449,0.0001522795,0.001066659,0.00002793607,0.0002789192,0.008809119],"study_design_scores_gemma":[0.0004467303,0.004147181,0.9926131,0.0000177058,0.0002553186,0.0006268423,0.00005389974,0.0002825392,0.0002848282,0.0000373458,0.001222016,0.00001243937],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978693,0.001518078,0.00008684035,0.00007594697,0.000005574532,0.00001458849,0.0001924542,0.000003643344,0.0002336139],"genre_scores_gemma":[0.9990102,0.0001973983,0.00006848785,0.00009598319,0.00002704265,0.00002421818,0.0004616271,0.000001632025,0.0001133207],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002372768,"threshold_uncertainty_score":0.01254857,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1981083415","doi":"10.1016/j.ccr.2005.10.015","title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein","year":2005,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":472,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Institutes of Health; National Cancer Institute; University of Pennsylvania","keywords":"Chronic myelogenous leukemia; Cancer research; Protein phosphatase 2; breakpoint cluster region; Progenitor cell; Imatinib mesylate; ABL; Biology; Imatinib; Leukemia; Stem cell; Cell biology; Phosphorylation; Immunology; Signal transduction; Phosphatase; Myeloid leukemia; Tyrosine kinase; Receptor; Genetics","authors":[{"name":"Paolo Neviani","is_ca":false},{"name":"Ramasamy Santhanam","is_ca":false},{"name":"Rossana Trotta","is_ca":false},{"name":"Mario Notari","is_ca":false},{"name":"Bradley W. Blaser","is_ca":false},{"name":"Shujun Liu","is_ca":false},{"name":"Hsiaoyin Mao","is_ca":false},{"name":"Ji Suk Chang","is_ca":false},{"name":"Annamaria Galietta","is_ca":false},{"name":"Ashwin Uttam","is_ca":false},{"name":"Denis‐Claude Roy","is_ca":true},{"name":"M Valtieri","is_ca":false},{"name":"Rebecca Bruner-Klisovic","is_ca":false},{"name":"Michael A. Caligiuri","is_ca":false},{"name":"Clara D. Bloomfield","is_ca":false},{"name":"Guido Marcucci","is_ca":false},{"name":"Danilo Perrotti","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01474678763094991,"gpt":0.2611239385216091,"spread":0.2463771508906592,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001639061,0.0002938246,0.0002664535,0.0003259221,0.0002473322,0.0005664304,0.0002500608,0.0001988675,0.001564595],"category_scores_gemma":[0.0001944405,0.000183396,0.0001804527,0.0002124149,0.000387228,0.0002051021,0.0003206362,0.0006959563,0.0006441278],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002991902,"about_ca_system_score_gemma":0.000198775,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002548263,"about_ca_topic_score_gemma":0.0003819888,"domain_scores_codex":[0.9998659,0.00002092311,0.000009044286,0.00002318773,0.00004874202,0.00003220796],"domain_scores_gemma":[0.9999218,0.00001466399,0.00001977479,0.00000977166,0.000004983713,0.00002899671],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002005413,0.00002473243,0.000352388,0.00002354956,0.000008201088,0.0001804819,0.000009022118,0.0001195857,0.9964491,0.0004550893,0.0002040161,0.001973269],"study_design_scores_gemma":[0.00007048246,0.0003040201,0.01344541,0.000006835327,0.00003503228,0.002898784,0.00005733665,0.002433253,0.9725533,0.0006912626,0.007494316,0.000009885872],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926813,0.002146625,0.00158412,0.0002234236,0.00006016369,0.000009303547,0.0003930157,0.0001241435,0.002777839],"genre_scores_gemma":[0.9977809,0.0004158286,0.0002804656,0.00003352099,0.00001127504,0.000006465313,0.0002968058,0.0000214447,0.00115339],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001564595,"threshold_uncertainty_score":0.005234063,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2004492241","doi":"10.1182/blood-2006-09-046839","title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":372,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Imatinib; Medicine; Internal medicine; Neutropenia; Myeloid leukemia; Adverse effect; Imatinib mesylate; Nilotinib; Gastroenterology; Oncology; Chemotherapy","authors":[{"name":"François Guilhot","is_ca":false},{"name":"Jane F. Apperley","is_ca":false},{"name":"Dong‐Wook Kim","is_ca":false},{"name":"Eduardo Bullorsky","is_ca":false},{"name":"Michele Baccarani","is_ca":false},{"name":"Gail J. Roboz","is_ca":false},{"name":"Sergio Amadori","is_ca":false},{"name":"Cármino Antônio De Souza","is_ca":false},{"name":"Jeffrey H. Lipton","is_ca":true},{"name":"Andreas Hochhaus","is_ca":false},{"name":"Dominik Heim","is_ca":false},{"name":"Richard A. Larson","is_ca":false},{"name":"Susan Branford","is_ca":false},{"name":"Martin C. Müller","is_ca":false},{"name":"Prasheen Agarwal","is_ca":false},{"name":"Ashwin Gollerkeri","is_ca":false},{"name":"Moshe Talpaz","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02939114940907976,"gpt":0.3000116606126729,"spread":0.2706205112035932,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003959706,0.0001706388,0.0003722615,0.0001158285,0.0001148342,0.0001414831,0.00008364706,0.0001116934,0.0008832294],"category_scores_gemma":[0.0005686168,0.00006007136,0.0001858463,0.0001251637,0.0001041392,0.0001070935,0.0001068526,0.0003274991,0.0001485341],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001210099,"about_ca_system_score_gemma":0.0001448676,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001288258,"about_ca_topic_score_gemma":0.0004646489,"domain_scores_codex":[0.9998258,0.00008551969,0.00001849283,0.00001490201,0.00002470924,0.00003071536],"domain_scores_gemma":[0.9998504,0.00004935222,0.00003296508,0.00001134613,0.00001118126,0.00004461396],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.0479278,0.005664841,0.08597803,0.0009378132,0.0005891986,0.002551106,0.0004969022,0.002479954,0.2810067,0.0003942582,0.005426671,0.5665466],"study_design_scores_gemma":[0.02179948,0.2039447,0.6423267,0.00006639371,0.0005424339,0.01375026,0.0002276126,0.00446651,0.0819746,0.0004997707,0.03034896,0.00005258841],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996973,0.001432476,0.000217598,0.00009576426,0.00001610331,0.00006685442,0.00007700864,0.00002791032,0.001093286],"genre_scores_gemma":[0.9990786,0.0003392918,0.0001505188,0.00005548197,0.0000221348,0.00001882483,0.0001285973,0.000002233982,0.0002042104],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008832294,"threshold_uncertainty_score":0.002954662,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2152713204","doi":"10.1158/0008-5472.can-06-1199","title":"<i>In vitro</i> and <i>In vivo</i> Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":371,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Imatinib; Chronic myelogenous leukemia; ABL; Cancer research; Imatinib mesylate; In vivo; Leukemia; Biology; breakpoint cluster region; Pharmacology; Receptor; Immunology; Tyrosine kinase; Genetics","authors":[{"name":"Miriam Puttini","is_ca":false},{"name":"Addolorata Maria Luce Coluccia","is_ca":false},{"name":"Frank Boschelli","is_ca":false},{"name":"Loredana Cleris","is_ca":false},{"name":"Edoardo Marchesi","is_ca":false},{"name":"Arianna Donella‐Deana","is_ca":false},{"name":"Shaheen Ahmed","is_ca":false},{"name":"Sara Redaelli","is_ca":false},{"name":"Rocco Piazza","is_ca":false},{"name":"Vera Magistroni","is_ca":false},{"name":"Federica Andreoni","is_ca":false},{"name":"Léonardo Scapozza","is_ca":false},{"name":"Franca Formelli","is_ca":false},{"name":"Carlo Gambacorti‐Passerini","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02715129866584341,"gpt":0.3319171761275068,"spread":0.3047658774616633,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002807337,0.0004117415,0.0004700908,0.0002404337,0.0001173851,0.0003304216,0.0001987707,0.0002557434,0.001425533],"category_scores_gemma":[0.0001718754,0.0001577801,0.0003167366,0.0001872526,0.0001806272,0.0001954627,0.0001216215,0.0006437034,0.0005139822],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002314687,"about_ca_system_score_gemma":0.0001724295,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006998559,"about_ca_topic_score_gemma":0.0008343712,"domain_scores_codex":[0.9998091,0.00006419839,0.00001997159,0.00002572624,0.00003884242,0.00004211627],"domain_scores_gemma":[0.9998112,0.00004957109,0.00005236335,0.00002661025,0.00001866079,0.0000415654],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0005930585,0.0002093503,0.0003528132,0.00008321609,0.00002054969,0.00002690264,0.00001687364,0.0002351184,0.9948434,0.00008183333,0.000218533,0.003318338],"study_design_scores_gemma":[0.00005130077,0.002471517,0.002803725,0.000005174833,0.00003479396,0.000210805,0.000008695206,0.0005990002,0.9923239,0.00002003042,0.001466944,0.000004037092],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888337,0.005308024,0.001569232,0.0001661407,0.00005057186,0.00003367971,0.0007792917,0.0001067293,0.003152654],"genre_scores_gemma":[0.991768,0.003061724,0.001489736,0.00008512075,0.0000355883,0.00003989229,0.001846887,0.00003308133,0.001639953],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001425533,"threshold_uncertainty_score":0.004768908,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2140351909","doi":"10.1016/j.ccr.2014.07.006","title":"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","year":2014,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":366,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health; National Heart, Lung, and Blood Institute; Huntsman Cancer Institute; University of Utah; American Society of Hematology; Leukemia and Lymphoma Society; Office of Science; Imperial College London; Howard Hughes Medical Institute","keywords":"Ponatinib; Cancer research; Protein kinase domain; Leukemia; ABL; Mutation; Biology; Philadelphia chromosome; breakpoint cluster region; Drug resistance; Kinase; Myeloid leukemia; Genetics; Tyrosine kinase; Dasatinib; Chromosomal translocation; Imatinib; Signal transduction; Gene; Mutant","authors":[{"name":"Matthew S. Zabriskie","is_ca":false},{"name":"Christopher A. Eide","is_ca":false},{"name":"Srinivas K. Tantravahi","is_ca":false},{"name":"Nadeem A. Vellore","is_ca":false},{"name":"Johanna Estrada","is_ca":false},{"name":"Franck E. Nicolini","is_ca":false},{"name":"H. Jean Khoury","is_ca":false},{"name":"Richard A. Larson","is_ca":false},{"name":"Marina Konopleva","is_ca":false},{"name":"Jörge E. Cortes","is_ca":false},{"name":"Hagop M. Kantarjian","is_ca":false},{"name":"Elias Jabbour","is_ca":false},{"name":"Steven M. Kornblau","is_ca":false},{"name":"Jeffrey H. Lipton","is_ca":true},{"name":"Delphine Réa","is_ca":false},{"name":"Leif Stenke","is_ca":false},{"name":"Gisela Barbany","is_ca":false},{"name":"Thoralf Lange","is_ca":false},{"name":"Juan Carlos Hernández‐Boluda","is_ca":false},{"name":"Gert J. Ossenkoppele","is_ca":false},{"name":"Richard D. Press","is_ca":false},{"name":"Charles Chuah","is_ca":false},{"name":"Stuart L. Goldberg","is_ca":false},{"name":"Meir Wetzler","is_ca":false},{"name":"François-Xavier Mahon","is_ca":false},{"name":"Gabriel Étienne","is_ca":false},{"name":"Michele Baccarani","is_ca":false},{"name":"Simona Soverini","is_ca":false},{"name":"Gianantonio Rosti","is_ca":false},{"name":"Philippe Rousselot","is_ca":false},{"name":"Ran Friedman","is_ca":false},{"name":"Marie Deininger","is_ca":false},{"name":"Kimberly R. Reynolds","is_ca":false},{"name":"William L. Heaton","is_ca":false},{"name":"Anna M. Eiring","is_ca":false},{"name":"Anthony D. Pomicter","is_ca":false},{"name":"Jamshid S. Khorashad","is_ca":false},{"name":"Todd W. Kelley","is_ca":false},{"name":"Riccardo Baron","is_ca":false},{"name":"Brian Druker","is_ca":false},{"name":"Michael W. Deininger","is_ca":false},{"name":"Thomas O’Hare","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0224330624772539,"gpt":0.3231792071203803,"spread":0.3007461446431264,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002743037,0.0002078268,0.0004994846,0.000311001,0.0002258147,0.0003950759,0.0002641683,0.0003511024,0.003688351],"category_scores_gemma":[0.0004626011,0.0001384815,0.0002009185,0.0003057276,0.0003066197,0.0002509445,0.0002199125,0.0006905513,0.0003618102],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004029686,"about_ca_system_score_gemma":0.0003131498,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008541637,"about_ca_topic_score_gemma":0.001552498,"domain_scores_codex":[0.9997931,0.00003732392,0.00001968176,0.00002273442,0.00005516307,0.00007196528],"domain_scores_gemma":[0.9998873,0.00003962678,0.00001405098,0.0000146039,0.00001141833,0.00003294414],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.004556033,0.0009348827,0.006443696,0.00008021932,0.00007314299,0.0009116067,0.00008663476,0.001104616,0.955119,0.0009368127,0.001467537,0.02828589],"study_design_scores_gemma":[0.002159698,0.01861294,0.1090869,0.00002023458,0.0003138281,0.01761202,0.0002867612,0.008755288,0.8223119,0.0007529635,0.02003781,0.0000497514],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973453,0.0002601706,0.0001982234,0.0001245891,0.00001993914,0.00002401548,0.0002075197,0.00002371922,0.001796505],"genre_scores_gemma":[0.9988039,0.0001441151,0.0001528855,0.00003058201,0.00000690452,0.000007802819,0.0002953389,0.000005510226,0.0005530996],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003688351,"threshold_uncertainty_score":0.01233882,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2112127173","doi":"10.1084/jem.191.6.977","title":"Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XL","year":2000,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":364,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"University of Toronto; University of Minnesota","keywords":"Chronic myelogenous leukemia; STAT protein; STAT5; breakpoint cluster region; Cancer research; ABL; K562 cells; Signal transduction; Apoptosis; Biology; Kinase; Leukemia; STAT3; Cell biology; Tyrosine kinase; Immunology; Receptor","authors":[{"name":"Machiko Horita","is_ca":false},{"name":"Enrique J. Andreu","is_ca":false},{"name":"Adalberto Benito","is_ca":false},{"name":"Cristina Arbona","is_ca":false},{"name":"Cristina Sanz","is_ca":false},{"name":"Isana Benet","is_ca":false},{"name":"Felipe Prósper","is_ca":false},{"name":"José L. Fernández-Luna","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0144349625745394,"gpt":0.2611755670376567,"spread":0.2467406044631173,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001253197,0.0002304579,0.0001500122,0.0001312525,0.0001163102,0.0001924017,0.0001008655,0.0001249527,0.001041368],"category_scores_gemma":[0.00006357025,0.00007444774,0.0001172601,0.000128541,0.0001697937,0.0001185392,0.0001253594,0.0005074539,0.0001899181],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001835814,"about_ca_system_score_gemma":0.0001926716,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002122271,"about_ca_topic_score_gemma":0.0004479504,"domain_scores_codex":[0.9999067,0.00001358536,0.000008825586,0.00001139943,0.00002689257,0.00003256261],"domain_scores_gemma":[0.9999598,0.00000948861,0.00001125888,0.000005984802,0.00000347452,0.00001002287],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001393026,0.00007220187,0.0001483754,0.00002835991,0.00000392051,0.00002574611,0.000009635559,0.00005480893,0.9970466,0.0001951687,0.00004185735,0.002233973],"study_design_scores_gemma":[0.0001182807,0.0008888957,0.00402565,0.000007570757,0.00001612724,0.0002621009,0.00001815978,0.001018017,0.9897025,0.0001048017,0.003835235,0.000002571039],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959682,0.001598003,0.001086145,0.0001024591,0.00001908382,0.00002067812,0.0001283428,0.00002825318,0.001048812],"genre_scores_gemma":[0.9971968,0.000972023,0.0007100446,0.00002989682,0.00001062887,0.00002093713,0.0002294991,0.000003684021,0.0008265525],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001041368,"threshold_uncertainty_score":0.003483772,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2012153991","doi":"10.1038/sj.leu.2404609","title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","year":2007,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":358,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"CD38; Imatinib mesylate; Myeloid leukemia; Stem cell; Haematopoiesis; Cancer research; Biology; CD34; Myeloid; breakpoint cluster region; Leukemia; Imatinib; Immunology; Cell biology; Receptor; Genetics","authors":[{"name":"Xiaoyan Jiang","is_ca":true},{"name":"Yun Zhao","is_ca":true},{"name":"Clayton A. Smith","is_ca":true},{"name":"Maura Gasparetto","is_ca":true},{"name":"Ali G. Turhan","is_ca":false},{"name":"AC Eaves","is_ca":true},{"name":"Connie J. Eaves","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01218732001443293,"gpt":0.2583148605492473,"spread":0.2461275405348144,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001833858,0.0002652354,0.0005279905,0.0005185143,0.0002398652,0.0005868702,0.0001700033,0.0003975987,0.002106454],"category_scores_gemma":[0.0002281625,0.0001352226,0.0001923133,0.0003547152,0.000283372,0.0002883449,0.0002908707,0.0006249559,0.0004182042],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002363151,"about_ca_system_score_gemma":0.0001987239,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002115813,"about_ca_topic_score_gemma":0.0006900359,"domain_scores_codex":[0.9998447,0.00001974591,0.00001238085,0.00001777646,0.00007390306,0.00003146534],"domain_scores_gemma":[0.9998555,0.00002879512,0.00003745662,0.00002449709,0.00002448149,0.00002936367],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.000320973,0.0002196651,0.01184912,0.0001524226,0.00005429802,0.0006828731,0.0001732239,0.000723296,0.906685,0.003973133,0.001667125,0.07349886],"study_design_scores_gemma":[0.0002259757,0.002436117,0.1018303,0.00002766929,0.000160436,0.01681109,0.000346671,0.002994961,0.816942,0.002504088,0.05568948,0.00003129366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818248,0.004148012,0.00360139,0.0007977106,0.00004339586,0.000114746,0.0005802984,0.0001397498,0.008749898],"genre_scores_gemma":[0.9943804,0.001167554,0.001326456,0.000174212,0.00003119124,0.00005484068,0.0005585524,0.00001061721,0.002296251],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002106454,"threshold_uncertainty_score":0.007046819,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1990020715","doi":"10.1038/leu.2008.84","title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":354,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Medicine; Imatinib; Chronic myelogenous leukemia; Internal medicine; Gastroenterology; Neutropenia; Imatinib mesylate; Leukemia; Oncology; Chemotherapy; Myeloid leukemia","authors":[{"name":"Andreas Hochhaus","is_ca":false},{"name":"Michele Baccarani","is_ca":false},{"name":"Michael W. Deininger","is_ca":false},{"name":"Jane F. Apperley","is_ca":false},{"name":"Jeffrey H. Lipton","is_ca":true},{"name":"Stuart L. Goldberg","is_ca":false},{"name":"Sélim Corm","is_ca":false},{"name":"Neil P. Shah","is_ca":false},{"name":"Francisco Cervantes","is_ca":false},{"name":"Richard T. Silver","is_ca":false},{"name":"Dietger Niederwieser","is_ca":false},{"name":"Richard M. Stone","is_ca":false},{"name":"Hervé Dombret","is_ca":false},{"name":"Richard A. Larson","is_ca":false},{"name":"Lydia Roy","is_ca":false},{"name":"Timothy P. Hughes","is_ca":false},{"name":"Martin C. Müller","is_ca":false},{"name":"Rana Ezzeddine","is_ca":false},{"name":"Athena Countouriotis","is_ca":false},{"name":"H. Kantarjian","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02218488206773787,"gpt":0.2795651517636827,"spread":0.2573802696959449,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002921411,0.0002043477,0.0008105345,0.0001690588,0.000204223,0.0003313317,0.000166188,0.0002366098,0.002086886],"category_scores_gemma":[0.0006373334,0.0001183775,0.0003174555,0.0003199757,0.0002371638,0.0002431195,0.0001802955,0.0005989074,0.0003794777],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002969344,"about_ca_system_score_gemma":0.000331484,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003410404,"about_ca_topic_score_gemma":0.001253,"domain_scores_codex":[0.9998629,0.00003539408,0.00001421926,0.00001839004,0.00001755931,0.00005156462],"domain_scores_gemma":[0.999768,0.00006711163,0.00004992862,0.00003382759,0.00001477665,0.00006640672],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1041774,0.006034006,0.09029489,0.0007144499,0.001443409,0.00359014,0.0005549049,0.003900861,0.2952724,0.001042487,0.01095788,0.4820172],"study_design_scores_gemma":[0.07859839,0.1626171,0.5416006,0.00008564237,0.001503164,0.024556,0.0007915471,0.006780681,0.1342681,0.001899372,0.04718263,0.0001166916],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963736,0.001262915,0.0002032412,0.0002933804,0.00003840321,0.00005011672,0.0002098862,0.00003969408,0.001528782],"genre_scores_gemma":[0.998904,0.000264574,0.000114342,0.00007576681,0.0000180156,0.00001532037,0.0003141499,0.000004799468,0.0002891753],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002086886,"threshold_uncertainty_score":0.006981313,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3195243079","doi":"10.1182/blood.2020009984","title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":336,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research; Novartis Pharmaceuticals Corporation","keywords":"Bosutinib; Medicine; Open label; Randomized controlled trial; Internal medicine; Oncology; Imatinib; Nilotinib; Myeloid leukemia","authors":[{"name":"Delphine Réa","is_ca":false},{"name":"Michael J. Mauro","is_ca":false},{"name":"Carla Boquimpani","is_ca":false},{"name":"Yosuke Minami","is_ca":false},{"name":"Elza Lomaia","is_ca":false},{"name":"Sergey Voloshin","is_ca":false},{"name":"Anna Turkina","is_ca":false},{"name":"Dong‐Wook Kim","is_ca":true},{"name":"Jane F. Apperley","is_ca":false},{"name":"André Abdo","is_ca":false},{"name":"Laura Fogliatto","is_ca":false},{"name":"Dennis Dong Hwan Kim","is_ca":true},{"name":"Philipp le Coutre","is_ca":false},{"name":"Susanne Saußele","is_ca":false},{"name":"Mario Annunziata","is_ca":false},{"name":"Timothy P. Hughes","is_ca":false},{"name":"Naeem Chaudhri","is_ca":false},{"name":"Koji Sasaki","is_ca":false},{"name":"Lynette Chee","is_ca":false},{"name":"Valentín García‐Gutiérrez","is_ca":false},{"name":"Jörge E. Cortes","is_ca":false},{"name":"Paola Aimone","is_ca":false},{"name":"Alex Allepuz","is_ca":false},{"name":"Sara Quenet","is_ca":false},{"name":"Véronique Bédoucha","is_ca":false},{"name":"Andreas Hochhaus","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0352400247850263,"gpt":0.3536891511236019,"spread":0.3184491263385756,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002858302,0.001852707,0.003032355,0.0004948673,0.0005174862,0.001330808,0.0009046187,0.001648251,0.004825438],"category_scores_gemma":[0.00227014,0.0007731278,0.002339632,0.0004295019,0.001291066,0.001292135,0.0004370833,0.00389642,0.0008762046],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001006078,"about_ca_system_score_gemma":0.001582945,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00101729,"about_ca_topic_score_gemma":0.003003028,"domain_scores_codex":[0.9990395,0.0005794595,0.00004386587,0.0001102503,0.00006354812,0.0001634076],"domain_scores_gemma":[0.9981078,0.0006845522,0.0004211333,0.0001140714,0.00008354132,0.0005890152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9814715,0.009414114,0.0003226839,0.0001619221,0.0004299403,0.00002790774,0.00003159278,0.000247064,0.001778357,0.00006159794,0.0003562288,0.005696883],"study_design_scores_gemma":[0.8631331,0.1339746,0.001335976,0.00001750947,0.000274946,0.00002489464,0.00002063545,0.0004884404,0.0002931693,0.0001387033,0.000283835,0.00001428481],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992246,0.002129368,0.0003876894,0.0005123951,0.000454374,0.002588457,0.0005847878,0.00006949409,0.001027568],"genre_scores_gemma":[0.9900978,0.001608715,0.001076702,0.001128501,0.0005055831,0.00325401,0.000577565,0.00002048811,0.001730691],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004825438,"threshold_uncertainty_score":0.01614273,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1975748957","doi":"10.1172/jci31095","title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":332,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Cancer Institute; D. Warren Brown Family Foundation; Associazione Italiana per la Ricerca sul Cancro; Fonds de Recherche du Québec - Santé; Ministero della Salute; Ohio State University; American-Italian Cancer Foundation","keywords":"Chronic myelogenous leukemia; Cancer research; Philadelphia chromosome; Leukemia; Dasatinib; Progenitor cell; Medicine; Myeloid leukemia; Immunology; Imatinib; Stem cell; Biology","authors":[{"name":"Paolo Neviani","is_ca":false},{"name":"Ramasamy Santhanam","is_ca":false},{"name":"Joshua J. Oaks","is_ca":false},{"name":"Anna M. Eiring","is_ca":false},{"name":"Mario Notari","is_ca":false},{"name":"Bradley W. Blaser","is_ca":false},{"name":"Shujun Liu","is_ca":false},{"name":"Rossana Trotta","is_ca":false},{"name":"Natarajan Muthusamy","is_ca":false},{"name":"Carlo Gambacorti‐Passerini","is_ca":false},{"name":"Brian Druker","is_ca":false},{"name":"Jörge E. Cortes","is_ca":false},{"name":"Guido Marcucci","is_ca":false},{"name":"Ching-Shih Chen","is_ca":false},{"name":"Nicole M. Verrills","is_ca":false},{"name":"Denis‐Claude Roy","is_ca":true},{"name":"Michael A. Caligiuri","is_ca":false},{"name":"Clara D. Bloomfield","is_ca":false},{"name":"John C. Byrd","is_ca":false},{"name":"Danilo Perrotti","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05296610249043909,"gpt":0.3724998987889664,"spread":0.3195337962985273,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006782242,0.0002948877,0.0002458064,0.0003220826,0.0001574508,0.0002145066,0.0002303905,0.0002962959,0.001093714],"category_scores_gemma":[0.00004087228,0.00006591371,0.000180962,0.0002255658,0.0001512023,0.000208699,0.0001433633,0.0005146592,0.0002899059],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003124901,"about_ca_system_score_gemma":0.0001907497,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006395927,"about_ca_topic_score_gemma":0.002073105,"domain_scores_codex":[0.9999663,0.000002927876,0.000002607877,0.000006626952,0.00001019446,0.00001128044],"domain_scores_gemma":[0.9999878,0.000001219704,0.000003927252,7.720108e-7,0.000001272843,0.000004962083],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.002980138,0.0008367944,0.001087042,0.0007014935,0.00007975383,0.002097487,0.00009523481,0.0006903215,0.6333331,0.00253293,0.004791805,0.3507739],"study_design_scores_gemma":[0.007145882,0.02431135,0.0294869,0.0001632701,0.0004162863,0.02986269,0.0001555872,0.00342012,0.5682725,0.001680062,0.3349831,0.0001021184],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8434346,0.1372796,0.004901798,0.001482308,0.0004668939,0.0002256654,0.0005875234,0.0005374667,0.01108416],"genre_scores_gemma":[0.9610122,0.03000962,0.002196384,0.0003173716,0.0001455664,0.00008927826,0.0007645739,0.00001347646,0.005451546],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001093714,"threshold_uncertainty_score":0.003658831,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2119584141","doi":"10.1016/j.jtbi.2005.03.033","title":"A mathematical model of hematopoiesis—I. Periodic chronic myelogenous leukemia","year":2005,"lang":"en","type":"article","venue":"Journal of Theoretical Biology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":276,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"Natural Sciences and Engineering Research Council of Canada; Mitacs","keywords":"Haematopoiesis; Chronic myelogenous leukemia; Stem cell; Leukemia; Biology; Hematopoietic stem cell; Immunology; Platelet; Cell biology; Cancer research","authors":[{"name":"Caroline Colijn","is_ca":true},{"name":"Michael C. Mackey","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01444154634903463,"gpt":0.2819608383042284,"spread":0.2675192919551937,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007084007,0.000432331,0.0005607752,0.0004337479,0.0006572216,0.001291076,0.001067056,0.001517177,0.00282686],"category_scores_gemma":[0.002343692,0.0002271664,0.0005262397,0.0005499528,0.001407621,0.001447754,0.0009180155,0.001379563,0.0002754921],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001273526,"about_ca_system_score_gemma":0.000806006,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002369858,"about_ca_topic_score_gemma":0.001357069,"domain_scores_codex":[0.9997782,0.0001067397,0.000008654367,0.00002584175,0.00004483847,0.00003571249],"domain_scores_gemma":[0.9994711,0.0002459867,0.0001183312,0.00002968314,0.00004946216,0.000085413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.00001487112,0.00002007007,0.000359315,0.00004070134,0.000009095182,0.0001197142,0.00007735175,0.03121391,0.0003843386,0.9640115,0.001642477,0.002106694],"study_design_scores_gemma":[0.00005626903,0.00004889904,0.0003517372,0.00003256282,0.00001506615,0.0002701406,0.00007328717,0.2719014,0.000114679,0.7231858,0.003933661,0.00001650208],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"methods","genre_gemma":"empirical","genre_scores_codex":[0.272795,0.01438556,0.5178047,0.03799535,0.00119731,0.0001687491,0.0009229414,0.0001696494,0.1545607],"genre_scores_gemma":[0.9573701,0.00391274,0.0164484,0.0009048274,0.000586099,0.0001432855,0.0001395666,0.00002402279,0.02047099],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.00282686,"threshold_uncertainty_score":0.009456813,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2339943063","doi":"10.1016/s1470-2045(16)00080-2","title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Ariad Pharmaceuticals","keywords":"Ponatinib; Medicine; Imatinib; Internal medicine; Myeloid leukemia; Imatinib mesylate; Oncology; Clinical trial; Clinical endpoint; Nilotinib","authors":[{"name":"Jeffrey H. Lipton","is_ca":true},{"name":"Charles Chuah","is_ca":false},{"name":"Agnès Guerci‐Bresler","is_ca":false},{"name":"Gianantonio Rosti","is_ca":false},{"name":"David Simpson","is_ca":false},{"name":"Sarit Assouline","is_ca":true},{"name":"Gabriel Étienne","is_ca":false},{"name":"Franck E. Nicolini","is_ca":false},{"name":"Philipp le Coutre","is_ca":false},{"name":"Leif Stenke","is_ca":false},{"name":"David Andorsky","is_ca":false},{"name":"Vivian G. Oehler","is_ca":false},{"name":"Stephanie Lustgarten","is_ca":false},{"name":"Victor M. Rivera","is_ca":false},{"name":"Timothy Piers Clackson","is_ca":false},{"name":"Frank G. Haluska","is_ca":false},{"name":"Michele Baccarani","is_ca":false},{"name":"Jörge E. Cortes","is_ca":false},{"name":"François Guilhot","is_ca":false},{"name":"Andreas Hochhaus","is_ca":false},{"name":"Timothy P. Hughes","is_ca":false},{"name":"Hagop M. Kantarjian","is_ca":false},{"name":"Neil P. Shah","is_ca":false},{"name":"Moshe Talpaz","is_ca":false},{"name":"Michael Deininger","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1491709117621627,"gpt":0.447745619994161,"spread":0.2985747082319983,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001946262,0.002114022,0.003700181,0.0003424553,0.000421213,0.001398516,0.0009461723,0.001742079,0.00657937],"category_scores_gemma":[0.002613864,0.00055399,0.002832915,0.0004846224,0.001424244,0.002176594,0.0006515087,0.00427088,0.001120925],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009884142,"about_ca_system_score_gemma":0.001052658,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008079204,"about_ca_topic_score_gemma":0.002318675,"domain_scores_codex":[0.9990864,0.0004832871,0.00006130119,0.0001606031,0.00006709012,0.000141354],"domain_scores_gemma":[0.9989629,0.0003373433,0.0002340741,0.00008269498,0.00005226845,0.0003306522],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9686752,0.001658546,0.000480454,0.001284926,0.00210727,0.00006762725,0.00008095389,0.0005991337,0.001656066,0.0002803355,0.001389066,0.02172039],"study_design_scores_gemma":[0.9776306,0.0188844,0.001025114,0.00004778013,0.0005819194,0.0000823647,0.00003365743,0.0002680377,0.000143987,0.0003769967,0.0009069225,0.00001826889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9653817,0.01982013,0.001582693,0.002511382,0.001368021,0.003159296,0.001689781,0.0001952607,0.004291773],"genre_scores_gemma":[0.9821748,0.007073043,0.001587893,0.001739522,0.0003927189,0.00249522,0.001328175,0.000037004,0.00317158],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00657937,"threshold_uncertainty_score":0.02201021,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2130008150","doi":"10.1073/pnas.0900189106","title":"Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation","year":2009,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; University of California, San Diego","keywords":"Biology; Progenitor cell; Cancer research; Stem cell; Wnt signaling pathway; Myeloid leukemia; Cancer stem cell; Haematopoiesis; Leukemia; Population; Immunology; Cell biology; Medicine; Signal transduction","authors":[{"name":"Annelie Abrahamsson","is_ca":false},{"name":"Ifat Geron","is_ca":false},{"name":"Jason Gotlib","is_ca":false},{"name":"Kim-Hien T. Dao","is_ca":false},{"name":"Charlene F. Barroga","is_ca":false},{"name":"Isabel G. Newton","is_ca":false},{"name":"Francis J. Giles","is_ca":false},{"name":"Jeffrey A. Durocher","is_ca":false},{"name":"Rémi J. Creusot","is_ca":false},{"name":"Mobin Karimi","is_ca":false},{"name":"Carol D. Jones","is_ca":false},{"name":"James L. Zehnder","is_ca":false},{"name":"Armand Keating","is_ca":true},{"name":"Robert S. Negrin","is_ca":false},{"name":"Irving L. Weissman","is_ca":false},{"name":"Catriona Jamieson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04238527604128569,"gpt":0.3078284576067045,"spread":0.2654431815654188,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001585635,0.0002795876,0.0001970514,0.0002255417,0.0001373176,0.0003987489,0.0001726919,0.0002315923,0.001918756],"category_scores_gemma":[0.0001608415,0.000185972,0.0002183276,0.0001010278,0.0001950702,0.0001789904,0.0004114929,0.0005982133,0.0008892649],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000276179,"about_ca_system_score_gemma":0.0003179844,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003100126,"about_ca_topic_score_gemma":0.000451494,"domain_scores_codex":[0.9998958,0.00001108657,0.000009545497,0.00002888864,0.0000340458,0.00002057954],"domain_scores_gemma":[0.9998241,0.00002412017,0.00005778843,0.00002719199,0.00001223602,0.00005451237],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00005722173,0.000009161354,0.00082477,0.00002648712,0.000003344346,0.000102629,0.00001169337,0.00007822968,0.996543,0.0003420427,0.00006416222,0.001937252],"study_design_scores_gemma":[0.00002978567,0.00009246555,0.0163446,0.00001570178,0.00002550114,0.001215432,0.00004085714,0.00365197,0.9703772,0.0005529139,0.007646133,0.000007465488],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987336,0.002151313,0.006835554,0.0002154813,0.00003885395,0.000034477,0.0004835128,0.0003050183,0.002599923],"genre_scores_gemma":[0.994976,0.0006565826,0.001530282,0.00006970192,0.00000990895,0.00001696377,0.0006113898,0.00005341154,0.00207564],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001918756,"threshold_uncertainty_score":0.006418884,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2084452268","doi":"10.1182/blood-2003-09-3032","title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":238,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Imatinib mesylate; Imatinib; Nausea; Pharmacokinetics; Internal medicine; Gastroenterology; Vomiting; Myeloid leukemia; Philadelphia chromosome; Chromosomal translocation","authors":[{"name":"Martin Champagne","is_ca":true},{"name":"Renaud Capdeville","is_ca":false},{"name":"Mark Krailo","is_ca":false},{"name":"Wenchun Qu","is_ca":false},{"name":"Bin Peng","is_ca":false},{"name":"Marianne Rosamilia","is_ca":false},{"name":"Martine Therrien","is_ca":false},{"name":"Ulrike Zoellner","is_ca":false},{"name":"Susan M. Blaney","is_ca":false},{"name":"Mark L. Bernstein","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01754745499324663,"gpt":0.2983391117999296,"spread":0.280791656806683,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001144925,0.0005134245,0.001084429,0.0002122934,0.0001779116,0.0003059148,0.0003327984,0.0004399259,0.001170649],"category_scores_gemma":[0.000769444,0.0001360496,0.0004658596,0.0003389602,0.0002941523,0.0002890793,0.0001454246,0.00093799,0.0002033193],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005553389,"about_ca_system_score_gemma":0.000893739,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008703977,"about_ca_topic_score_gemma":0.002339297,"domain_scores_codex":[0.999711,0.0001455257,0.0000229228,0.00003774695,0.00005101491,0.00003186449],"domain_scores_gemma":[0.9993181,0.0002172253,0.0001821537,0.00003057171,0.0000493798,0.0002025657],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1519911,0.01836,0.09665046,0.002469391,0.00310192,0.001427219,0.0006332648,0.006462175,0.1480886,0.0004903124,0.01210114,0.5582245],"study_design_scores_gemma":[0.1636993,0.4254925,0.3334954,0.0003350322,0.003194873,0.005941718,0.0001928324,0.002951192,0.03115497,0.0002929854,0.033159,0.00009022772],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871623,0.009913609,0.0003670912,0.0002951115,0.00002790272,0.0003081696,0.0009430132,0.00003345345,0.0009493101],"genre_scores_gemma":[0.9744193,0.0154249,0.002753902,0.0008116587,0.0001091176,0.0008050666,0.004622216,0.00003392794,0.00101984],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001170649,"threshold_uncertainty_score":0.006055057,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1997397403","doi":"10.1182/blood-2008-03-147744","title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":233,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Imatinib; Myeloid leukemia; Genotype; Single-nucleotide polymorphism; Pharmacogenetics; Imatinib mesylate; Haplotype; Allele; Medicine; Leukemia; Internal medicine; Immunology; Oncology; Biology; Genetics; Gene","authors":[{"name":"Stéphanie Dulucq","is_ca":false},{"name":"Stéphane Bouchet","is_ca":false},{"name":"Béatrice Turcq","is_ca":false},{"name":"Éric Lippert","is_ca":false},{"name":"Gabriel Étienne","is_ca":false},{"name":"Josy Reiffers","is_ca":false},{"name":"Mathiéu Molimard","is_ca":false},{"name":"Maja Krajinović","is_ca":true},{"name":"François‐Xavier Mahon","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01370123802848771,"gpt":0.248948420350487,"spread":0.2352471823219993,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006605356,0.0001937896,0.0003048995,0.0004565171,0.0002296606,0.0002232837,0.0001121568,0.0003329774,0.0009413133],"category_scores_gemma":[0.001763874,0.0001235227,0.0001810031,0.0004320835,0.0002651451,0.0001552567,0.0001825267,0.0004072583,0.0001489302],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001007474,"about_ca_system_score_gemma":0.00009794293,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003421225,"about_ca_topic_score_gemma":0.0005427589,"domain_scores_codex":[0.999588,0.0001729483,0.00004943196,0.00005436712,0.00008103946,0.00005427563],"domain_scores_gemma":[0.9989034,0.000376659,0.0004714191,0.0000494825,0.00005471747,0.0001442049],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001465247,0.0001412792,0.977886,0.00002029078,0.00008686645,0.0002148524,0.00008001597,0.0001496417,0.01192793,0.00004541515,0.0001479793,0.007834581],"study_design_scores_gemma":[0.00003801931,0.0003266468,0.997116,0.000004355683,0.00005260287,0.0008927244,0.00003550175,0.0002718575,0.0009984166,0.00005038114,0.0002093065,0.000004209235],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.999644,0.0001755829,0.0000449708,0.00002678682,0.000001511278,0.000002398938,0.00002463024,0.000001082357,0.00007904674],"genre_scores_gemma":[0.9997558,0.00006499419,0.00005443846,0.00001890698,0.000009141883,0.000002521892,0.00004767091,9.148472e-7,0.00004549658],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009413133,"threshold_uncertainty_score":0.003493309,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2412914653","doi":"10.1038/nature18288","title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","year":2016,"lang":"en","type":"article","venue":"Nature","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Discovery Centre","funders":"Medical Research Council; Imperial Experimental Cancer Medicine Centre; Howat Foundation; Cancer Research UK; Constellation Pharmaceuticals","keywords":"Stem cell; Cancer research; Tyrosine kinase; Haematopoiesis; Imatinib mesylate; Biology; Imatinib; Bruton's tyrosine kinase; breakpoint cluster region; Myeloid leukemia; Cell biology; Signal transduction; Receptor; Genetics","authors":[{"name":"Sheela A. Abraham","is_ca":false},{"name":"Lisa Hopcroft","is_ca":false},{"name":"Emma Carrick","is_ca":false},{"name":"Mark E. Drotar","is_ca":false},{"name":"Karen Dunn","is_ca":false},{"name":"Andrew J.K. Williamson","is_ca":false},{"name":"Koorosh Korfi","is_ca":false},{"name":"Pablo Baquero","is_ca":false},{"name":"Laura E. Park","is_ca":false},{"name":"Mary T. Scott","is_ca":false},{"name":"Francesca Pellicano","is_ca":false},{"name":"Andrew Pierce","is_ca":false},{"name":"Mhairi Copland","is_ca":false},{"name":"Craig Nourse","is_ca":false},{"name":"Sean M. Grimmond","is_ca":false},{"name":"David Vetrie","is_ca":false},{"name":"Anthony D. Whetton","is_ca":true},{"name":"Tessa L. Holyoake","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007148326169444772,"gpt":0.2449901059690739,"spread":0.2378417797996292,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019423,0.0003240402,0.0003625168,0.0004143892,0.0001962899,0.0005337312,0.000304078,0.0004526642,0.002695403],"category_scores_gemma":[0.0001317761,0.0001620735,0.0001980678,0.0001786588,0.000309141,0.000244811,0.0002459192,0.000922351,0.0005377606],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002767963,"about_ca_system_score_gemma":0.0002998981,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003524724,"about_ca_topic_score_gemma":0.001107987,"domain_scores_codex":[0.9997929,0.00002003942,0.00001438197,0.00004330021,0.00007342778,0.00005593309],"domain_scores_gemma":[0.9999036,0.00002007151,0.00002651088,0.0000145997,0.00000787936,0.00002745351],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002011157,0.000124124,0.0003751274,0.00003786788,0.00001605649,0.0000752634,0.0000164274,0.000177904,0.9867954,0.001161498,0.0004122938,0.01060698],"study_design_scores_gemma":[0.00008413559,0.0006806244,0.002207514,0.000008292093,0.00004222642,0.0006276209,0.00003037362,0.001377751,0.9853753,0.000272683,0.009288543,0.000005009615],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800656,0.003614353,0.0078001,0.0005411044,0.0001637021,0.00009550388,0.0004600486,0.0004412139,0.006818419],"genre_scores_gemma":[0.9937087,0.0006985288,0.001703492,0.00007800064,0.00002164657,0.00003378309,0.0002031958,0.00002617068,0.003526457],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002695403,"threshold_uncertainty_score":0.00901705,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015018636","doi":"10.1182/blood-2014-12-615757","title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":224,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; St. Baldrick's Foundation","keywords":"Medicine; Oncology; Internal medicine; Cohort","authors":[{"name":"Michael A. Pulsipher","is_ca":false},{"name":"Chris Carlson","is_ca":false},{"name":"Bryan Langholz","is_ca":false},{"name":"Donna A. Wall","is_ca":false},{"name":"Kirk R. Schultz","is_ca":true},{"name":"Nancy Bunin","is_ca":false},{"name":"Ilan R. Kirsch","is_ca":false},{"name":"Julie M. Gastier‐Foster","is_ca":false},{"name":"Michael J. Borowitz","is_ca":false},{"name":"Cindy Desmarais","is_ca":false},{"name":"David Williamson","is_ca":false},{"name":"Michael Kalos","is_ca":false},{"name":"Stephan A. Grupp","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01667898044994222,"gpt":0.2156055388238983,"spread":0.1989265583739561,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004501329,0.0002376051,0.0003583668,0.0003704839,0.0002256062,0.0005328321,0.0002306364,0.0003564662,0.000566058],"category_scores_gemma":[0.001330665,0.0001665446,0.000192017,0.0001971845,0.0003535407,0.0002868699,0.0003090656,0.0004945031,0.0002130197],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002791055,"about_ca_system_score_gemma":0.0001622453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008033258,"about_ca_topic_score_gemma":0.001088331,"domain_scores_codex":[0.9997008,0.00009462844,0.00002924249,0.00007279076,0.00004079926,0.000061873],"domain_scores_gemma":[0.9994104,0.0002222473,0.0001307882,0.00005974675,0.00003647759,0.000140398],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001297413,0.00009251297,0.9815317,0.000009585041,0.00002298891,0.00009972138,0.00009569016,0.0003161396,0.008976597,0.00002949302,0.000116776,0.007411279],"study_design_scores_gemma":[0.00005567072,0.00135793,0.9898171,0.00000922072,0.00005662366,0.0008936373,0.0001092459,0.001392686,0.005688845,0.00007975216,0.000529626,0.00000957871],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9995297,0.0001194574,0.00008950022,0.00001123647,0.000002370678,0.000004541405,0.00003806412,0.000004763811,0.0002002485],"genre_scores_gemma":[0.9996818,0.00002945046,0.00009382689,0.00001800904,0.000003502136,0.000005695251,0.0001028723,0.00000161482,0.0000631474],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008033258,"threshold_uncertainty_score":0.00238055,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2127016965","doi":"10.1182/blood.v97.11.3581","title":"Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis","year":2001,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Breakpoint; Haploinsufficiency; Biology; Chromosomal translocation; breakpoint cluster region; Myeloid leukemia; Leukemia; Fluorescence in situ hybridization; Comparative genomic hybridization; Genetics; Cytogenetics; Gene rearrangement; Molecular biology; Chromosome; Cancer research; Gene; Phenotype","authors":[{"name":"Elena Kolomietz","is_ca":true},{"name":"Jaudah Al‐Maghrabi","is_ca":true},{"name":"Shawn Brennan","is_ca":true},{"name":"Jana Karásková","is_ca":true},{"name":"Solomon Minkin","is_ca":true},{"name":"Jeffrey H. Lipton","is_ca":true},{"name":"Jeremy A. Squire","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01840919972254899,"gpt":0.26336061842172,"spread":0.244951418699171,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001385895,0.0001982937,0.0002693184,0.0003625161,0.0001533907,0.0001806343,0.00008126173,0.0001755806,0.002541909],"category_scores_gemma":[0.0005768935,0.0000659234,0.00009779351,0.0003122762,0.0001712984,0.0001056659,0.000233972,0.0001357854,0.0005999552],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001592316,"about_ca_system_score_gemma":0.00008676201,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002410417,"about_ca_topic_score_gemma":0.0003343277,"domain_scores_codex":[0.9999034,0.00001324598,0.000007143543,0.00002028972,0.00002368733,0.00003216105],"domain_scores_gemma":[0.99962,0.00004460253,0.0001720566,0.00003531273,0.00003523885,0.00009274165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001370666,0.00007971244,0.8005819,0.0001086956,0.00007291493,0.01228391,0.000131092,0.0004421074,0.1231827,0.0003292406,0.0009280471,0.06048891],"study_design_scores_gemma":[0.00001014854,0.0002731278,0.9688538,0.000008056008,0.00002591564,0.02342084,0.00004350322,0.0002315235,0.004702734,0.000270919,0.002152484,0.000006875414],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961686,0.001469813,0.0007195127,0.0000391102,0.000009390852,0.00001121491,0.0002758295,0.00007864843,0.001227942],"genre_scores_gemma":[0.9989624,0.0002990698,0.0001752655,0.0000104349,0.00001248977,0.000003620523,0.000226414,0.000004420028,0.0003058224],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002541909,"threshold_uncertainty_score":0.008503497,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1947838475","doi":"10.1182/blood-2015-06-648667","title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Child and Family Research Institute; BC Children's Hospital","funders":"National Cancer Institute; Ariad Pharmaceuticals; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Chronic myelogenous leukemia; Disease; Pediatrics; Transplantation; Myeloid leukemia; Hematopoietic stem cell transplantation; Dasatinib; Leukemia; Intensive care medicine; Immunology; Imatinib; Internal medicine","authors":[{"name":"Nobuko Hijiya","is_ca":false},{"name":"Kirk R. Schultz","is_ca":true},{"name":"Markus Metzler","is_ca":false},{"name":"Frédéric Millot","is_ca":false},{"name":"Meinolf Suttorp","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03734855655750234,"gpt":0.2647348544438029,"spread":0.2273862978863005,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002602023,0.0003529618,0.0006246986,0.0003937625,0.0008197066,0.0007925372,0.0002803801,0.0006493881,0.003300571],"category_scores_gemma":[0.0008674593,0.0001088242,0.0003132077,0.0005128999,0.000511319,0.0006821462,0.0006949838,0.001397257,0.001427527],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005767297,"about_ca_system_score_gemma":0.001528701,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001116128,"about_ca_topic_score_gemma":0.002263876,"domain_scores_codex":[0.9997579,0.00003838581,0.00003565079,0.00004923625,0.00006550459,0.00005329611],"domain_scores_gemma":[0.9995397,0.00006953829,0.00008592394,0.00002816689,0.00008782704,0.0001888854],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003415589,0.0003090246,0.1309143,0.001720571,0.0001485869,0.04383673,0.0005993949,0.0006346859,0.01494011,0.01365349,0.05657771,0.7363237],"study_design_scores_gemma":[0.0001001731,0.0005507608,0.09565395,0.00130054,0.0002200228,0.3969606,0.001619483,0.0003859819,0.004781866,0.008677514,0.4896689,0.0000801838],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.3141873,0.44638,0.0429747,0.04839515,0.004489107,0.0007056872,0.002041658,0.001169838,0.1396566],"genre_scores_gemma":[0.7390487,0.1894853,0.02674384,0.01823302,0.004528942,0.0003430766,0.002857786,0.0002326805,0.0185267],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.003300571,"threshold_uncertainty_score":0.01104152,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2134318552","doi":"10.1158/1078-0432.ccr-07-4575","title":"Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Imatinib; Medicine; Systemic mastocytosis; Tyrosine kinase; Dermatofibrosarcoma protuberans; Imatinib mesylate; Tyrosine-kinase inhibitor; PDGFRA; Malignancy; Cancer research; Internal medicine; GiST; Oncology; Pathology; Cancer; Disease; Receptor; Stromal cell","authors":[{"name":"Michael C. Heinrich","is_ca":false},{"name":"Heikki Joensuu","is_ca":false},{"name":"George D. Demetri","is_ca":false},{"name":"Christopher L. Corless","is_ca":false},{"name":"Jane F. Apperley","is_ca":false},{"name":"Jonathan A. Fletcher","is_ca":false},{"name":"Denis Soulières","is_ca":true},{"name":"Stephan Dirnhofer","is_ca":false},{"name":"Amy Harlow","is_ca":false},{"name":"Ajia Town","is_ca":false},{"name":"Arin McKinley","is_ca":false},{"name":"Shane G. Supple","is_ca":false},{"name":"John F. Seymour","is_ca":false},{"name":"Lilla Di Scala","is_ca":false},{"name":"A. van Oosterom","is_ca":false},{"name":"Richard Herrmann","is_ca":false},{"name":"Zariana Nikolova","is_ca":false},{"name":"and Grant McArthur","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.5138175632808544,"gpt":0.5818905854513831,"spread":0.06807302217052869,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001746755,0.001656088,0.002722602,0.0003525201,0.0003566376,0.0008953229,0.0009318313,0.001397345,0.004150865],"category_scores_gemma":[0.001370472,0.0005725695,0.0008824063,0.0003666593,0.001344956,0.00105234,0.0003298057,0.00273072,0.0007276714],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006069616,"about_ca_system_score_gemma":0.00128816,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002471136,"about_ca_topic_score_gemma":0.0006725963,"domain_scores_codex":[0.9992149,0.0004371442,0.00004801496,0.0001115359,0.00007948638,0.0001090077],"domain_scores_gemma":[0.9980368,0.0005835389,0.0005300465,0.000139383,0.00009085545,0.0006193904],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8272311,0.08128744,0.007246001,0.0008189142,0.0009545526,0.0003198449,0.0001668288,0.001578373,0.04040821,0.0001901047,0.001481245,0.03831742],"study_design_scores_gemma":[0.4798854,0.5067692,0.007178897,0.00002925808,0.0002240737,0.0002750198,0.00003497121,0.000909859,0.003392458,0.0001065711,0.001173354,0.00002091988],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994037,0.001817886,0.0006953185,0.0001630457,0.00007534152,0.001939376,0.0005438726,0.0000462719,0.0006818971],"genre_scores_gemma":[0.9874998,0.001687339,0.002344428,0.000706031,0.0003527143,0.004274463,0.001917771,0.00002094511,0.001196494],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004150865,"threshold_uncertainty_score":0.01388603,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1983717821","doi":"10.1038/sj.emboj.7601485","title":"Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation","year":2007,"lang":"en","type":"article","venue":"The EMBO Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro; Fondazione Italiana per la Ricerca sul Cancro; Ministero dell’Istruzione, dell’Università e della Ricerca","keywords":"Library science; Medicine; Humanities; Art; Computer science","authors":[{"name":"Addolorata Maria Luce Coluccia","is_ca":false},{"name":"Angelo Vacca","is_ca":false},{"name":"Mireia Duñach","is_ca":false},{"name":"Luca Mologni","is_ca":false},{"name":"Sara Redaelli","is_ca":false},{"name":"Victor Bustos","is_ca":false},{"name":"Daniela Benati","is_ca":false},{"name":"Lorenzo A. Pinna","is_ca":false},{"name":"Carlo Gambacorti‐Passerini","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02633029491608721,"gpt":0.2982616204707272,"spread":0.27193132555464,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001919003,0.0002739483,0.000173961,0.0002487103,0.0002983863,0.0003913939,0.0002089074,0.0003269223,0.002985451],"category_scores_gemma":[0.0001968628,0.0001661604,0.0002152107,0.0001562375,0.0002910807,0.0003059793,0.0003181027,0.0008470729,0.000746567],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004274902,"about_ca_system_score_gemma":0.0002039722,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004583271,"about_ca_topic_score_gemma":0.0007661402,"domain_scores_codex":[0.9998442,0.00002087079,0.000009230863,0.00002736656,0.00004220484,0.00005620171],"domain_scores_gemma":[0.9999253,0.00001051935,0.00002562594,0.000009378187,0.000007609767,0.0000215958],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.000319533,0.00005676539,0.0005216572,0.00007220135,0.00001855334,0.0001343399,0.00001948759,0.0001857651,0.9910783,0.0008767408,0.0004771014,0.006239437],"study_design_scores_gemma":[0.0001706408,0.0003348472,0.01004722,0.00001651314,0.00004285594,0.001208084,0.00005483235,0.001242606,0.973509,0.0005149691,0.01284747,0.00001104319],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868624,0.006409249,0.001560968,0.0008361333,0.00009138306,0.00002090492,0.0002534758,0.0001173895,0.003848081],"genre_scores_gemma":[0.9964666,0.0009709506,0.0002692837,0.00008235942,0.00001819681,0.00001033553,0.000172526,0.00001113559,0.001998625],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002985451,"threshold_uncertainty_score":0.009987295,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1605939038","doi":"10.1038/77819","title":"SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-Tα chain expression","year":2000,"lang":"en","type":"article","venue":"Nature Immunology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université du Québec; BioPhage Pharma (Canada); Université de Montréal; Montreal Clinical Research Institute","funders":"","keywords":"Transcription factor; Biology; CD8; Cell biology; Cellular differentiation; Thymocyte; T cell; Gene; Immunology; Genetics; Antigen; Immune system","authors":[{"name":"Sabine Herblot","is_ca":true},{"name":"Ann‐Muriel Steff","is_ca":true},{"name":"Patrice Hugo","is_ca":true},{"name":"Peter D. Aplan","is_ca":false},{"name":"Trang Hoang","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.004271264782695116,"gpt":0.2339531923296735,"spread":0.2296819275469784,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001620784,0.0002682559,0.0002028747,0.0004008632,0.0002337693,0.0003557003,0.0002382362,0.0003546319,0.003744956],"category_scores_gemma":[0.0001394528,0.0001397083,0.000220369,0.0002766615,0.0003971391,0.0002213761,0.0001536959,0.0007763725,0.0006557872],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004454574,"about_ca_system_score_gemma":0.0004331223,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001390162,"about_ca_topic_score_gemma":0.002944281,"domain_scores_codex":[0.9998465,0.00002591474,0.00001458529,0.00001722843,0.00002412948,0.00007179172],"domain_scores_gemma":[0.9998233,0.0000316385,0.00003154284,0.00001811647,0.00001020788,0.00008516527],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00164911,0.0002475566,0.0004035318,0.00003315627,0.000009761171,0.00007378128,0.00002388794,0.0001095166,0.994943,0.0002296588,0.0002158224,0.002061321],"study_design_scores_gemma":[0.0001318675,0.000613883,0.003282745,0.000003638836,0.00001443169,0.0001026483,0.00005404646,0.0003629189,0.993248,0.00005050046,0.002132456,0.000002803132],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959024,0.0004861332,0.0004437358,0.0001993164,0.00003560548,0.00001806447,0.0004500283,0.00006249802,0.002402304],"genre_scores_gemma":[0.9937688,0.0003931394,0.0005547646,0.00008278318,0.00001654218,0.00003658947,0.0006248555,0.00001982634,0.00450264],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003744956,"threshold_uncertainty_score":0.01252812,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2077014658","doi":"10.1002/pbc.21132","title":"A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study","year":2007,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children; Centre Hospitalier Universitaire Sainte-Justine; BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Imatinib mesylate; Sarcoma; Imatinib; Osteosarcoma; Neuroblastoma; Synovial sarcoma; Refractory (planetary science); Internal medicine; Oncology; Platelet-derived growth factor receptor; Surgical oncology; Pathology; Receptor","authors":[{"name":"Mason Bond","is_ca":true},{"name":"Mark L. Bernstein","is_ca":true},{"name":"Alberto S. Pappo","is_ca":true},{"name":"Kirk R. Schultz","is_ca":true},{"name":"Mark Krailo","is_ca":false},{"name":"Susan M. Blaney","is_ca":false},{"name":"Peter C. Adamson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01498889142586767,"gpt":0.3341036959074856,"spread":0.3191148044816179,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001358966,0.00113507,0.001877211,0.000296748,0.000358816,0.0005312134,0.0005935724,0.0009755716,0.002290444],"category_scores_gemma":[0.0007176716,0.0003552005,0.0009443546,0.0005520178,0.0007637023,0.0004150077,0.0003319935,0.002052824,0.0005185854],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00122203,"about_ca_system_score_gemma":0.002551729,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002193391,"about_ca_topic_score_gemma":0.00391313,"domain_scores_codex":[0.9994903,0.0002653275,0.00002837663,0.00007299396,0.0000620362,0.00008092404],"domain_scores_gemma":[0.9988961,0.0001335604,0.0002401349,0.00006121847,0.0000636761,0.0006051481],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5559527,0.05649449,0.1585217,0.002283794,0.005375605,0.003046378,0.001188639,0.005725847,0.07595329,0.001031531,0.01748652,0.1169394],"study_design_scores_gemma":[0.5466298,0.2701748,0.1538947,0.0001201756,0.00140302,0.002617146,0.0002099555,0.001256918,0.006323171,0.0002361214,0.01708109,0.00005307331],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912077,0.003151844,0.0002995195,0.0005160187,0.00005037683,0.001882371,0.001837406,0.0000322408,0.001022452],"genre_scores_gemma":[0.9790161,0.005518199,0.002967549,0.001140383,0.0001699624,0.00415885,0.005470499,0.000039299,0.001519154],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002290444,"threshold_uncertainty_score":0.008866489,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1827459324","doi":"10.1002/ajh.24120","title":"Age and d<scp>PCR</scp> can predict relapse in <scp>CML</scp> patients who discontinued imatinib: The <scp>ISAV</scp> study","year":2015,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"Regione Lombardia; Associazione Italiana per la Ricerca sul Cancro","keywords":"Imatinib; Medicine; Cancer research; Myeloid leukemia","authors":[{"name":"Silvia Mori","is_ca":false},{"name":"Elisabetta Vagge","is_ca":false},{"name":"Philipp le Coutre","is_ca":false},{"name":"Elisabetta Abruzzese","is_ca":false},{"name":"Bruno Martino","is_ca":false},{"name":"Ester Pungolino","is_ca":false},{"name":"Chiara Elena","is_ca":false},{"name":"Ivana Pierri","is_ca":false},{"name":"Sarit Assouline","is_ca":true},{"name":"Anna D’Emilio","is_ca":false},{"name":"Antonella Gozzini","is_ca":false},{"name":"Pilar Giraldo","is_ca":false},{"name":"Fabio Stagno","is_ca":false},{"name":"Alessandra Iurlo","is_ca":false},{"name":"Michela Luciani","is_ca":false},{"name":"Giulia De Riso","is_ca":false},{"name":"Sara Redaelli","is_ca":false},{"name":"Dong‐Wook Kim","is_ca":false},{"name":"Alessandra Pirola","is_ca":false},{"name":"Caterina Mezzatesta","is_ca":false},{"name":"Anna Petroccione","is_ca":false},{"name":"Agnese Lodolo D'Oria","is_ca":false},{"name":"Patrizia Crivori","is_ca":false},{"name":"Rocco Piazza","is_ca":false},{"name":"Carlo Gambacorti‐Passerini","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01461351741340303,"gpt":0.2685303413715195,"spread":0.2539168239581165,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001283588,0.0004103088,0.0005455025,0.0004710549,0.0002095084,0.0005659728,0.0003114256,0.0006779882,0.001112224],"category_scores_gemma":[0.00269043,0.0001873469,0.0006132325,0.0004223837,0.0002201372,0.0004482671,0.0002858189,0.0006676452,0.0003144373],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002006423,"about_ca_system_score_gemma":0.0002176911,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006618469,"about_ca_topic_score_gemma":0.000965004,"domain_scores_codex":[0.9996036,0.0001851177,0.00004459601,0.00006002069,0.00005871542,0.0000479899],"domain_scores_gemma":[0.9975933,0.0009173091,0.0006173358,0.0001569785,0.0001452317,0.000569774],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004036115,0.0001288767,0.9920013,0.00001280512,0.0001022658,0.00007815655,0.00002443007,0.0001046067,0.0004915728,0.00001069324,0.0001291939,0.002880041],"study_design_scores_gemma":[0.0003129764,0.002679367,0.993014,0.00001542223,0.0002500363,0.0005862954,0.0000681821,0.001700509,0.0004273533,0.00005517806,0.0008789019,0.00001173576],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9988135,0.0004614363,0.0000641751,0.00006662001,0.00001366924,0.00001167758,0.0001758145,0.000002990826,0.0003900634],"genre_scores_gemma":[0.9992581,0.0001255265,0.00008634333,0.0000477416,0.00003786922,0.000009442535,0.0002834309,0.000002145292,0.0001493956],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001283588,"threshold_uncertainty_score":0.006788313,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1998936478","doi":"10.1038/leu.2008.221","title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Dasatinib; Medicine; Internal medicine; Chronic myelogenous leukemia; Imatinib; Neutropenia; Tolerability; Gastroenterology; Imatinib mesylate; Myeloid leukemia; Oncology; Nilotinib; Immunology; Leukemia; Adverse effect; Chemotherapy","authors":[{"name":"Jörge E. Cortes","is_ca":false},{"name":"D-W Kim","is_ca":false},{"name":"Emmanuel Raffoux","is_ca":false},{"name":"Giovanni Martinelli","is_ca":false},{"name":"Ellen K. Ritchie","is_ca":false},{"name":"Lydia Roy","is_ca":false},{"name":"Steven Coutré","is_ca":false},{"name":"Sélim Corm","is_ca":false},{"name":"Nelson Hamerschlak","is_ca":false},{"name":"Andreas Hochhaus","is_ca":false},{"name":"H. Jean Khoury","is_ca":false},{"name":"Tim H. Brümmendorf","is_ca":false},{"name":"Mauricette Michallet","is_ca":false},{"name":"Giovanna Rege‐Cambrin","is_ca":false},{"name":"Carlo Gambacorti‐Passerini","is_ca":true},{"name":"Jerald P. Radich","is_ca":false},{"name":"Thomas Ernst","is_ca":false},{"name":"Chao Zhu","is_ca":false},{"name":"Jan Van Tornout","is_ca":false},{"name":"Moshe Talpaz","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01500029936148646,"gpt":0.2662409921901603,"spread":0.2512406928286739,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006044558,0.0002416283,0.001155991,0.0001983628,0.000199912,0.0003849392,0.0001979223,0.0003000051,0.001088532],"category_scores_gemma":[0.001218674,0.0001032798,0.000653185,0.0003242899,0.0003290918,0.00048353,0.0001665033,0.0007977296,0.0002046589],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004167276,"about_ca_system_score_gemma":0.0002983926,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004146411,"about_ca_topic_score_gemma":0.001038083,"domain_scores_codex":[0.9996874,0.0001341197,0.00004339204,0.00003992794,0.00003880049,0.00005635809],"domain_scores_gemma":[0.9996002,0.0001158945,0.0001286441,0.00003567101,0.00002680338,0.00009267837],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4935256,0.00443971,0.1308664,0.0009805039,0.002749045,0.001102045,0.0004512959,0.006751735,0.04431606,0.0007504214,0.002702998,0.3113642],"study_design_scores_gemma":[0.1362164,0.2922042,0.516454,0.0001180055,0.003560455,0.006214614,0.0005338643,0.007808641,0.02357738,0.001486587,0.01170266,0.0001231616],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961623,0.002396979,0.00008558235,0.0001718501,0.00002305439,0.00003307085,0.0001897561,0.00001031029,0.0009270555],"genre_scores_gemma":[0.9989982,0.000456361,0.00005904277,0.00006656297,0.00002446507,0.00001360616,0.0002243788,0.000002244794,0.0001552235],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001155991,"threshold_uncertainty_score":0.003641486,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1999328539","doi":"10.1182/blood-2013-07-516807","title":"The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Simon Fraser University; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Progenitor cell; Autophagy; Stem cell; Gene knockdown; Cancer research; Progenitor; Biology; Cell biology; Cell culture; Apoptosis; Genetics","authors":[{"name":"Katharina Rothe","is_ca":true},{"name":"Hanyang Lin","is_ca":true},{"name":"Kevin B.L. Lin","is_ca":true},{"name":"Amy Leung","is_ca":false},{"name":"Hui Mi Wang","is_ca":true},{"name":"Mehrnoush Malekesmaeili","is_ca":true},{"name":"Ryan R. Brinkman","is_ca":true},{"name":"Donna L. Forrest","is_ca":true},{"name":"Sharon M. Gorski","is_ca":true},{"name":"Xiaoyan Jiang","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01506847254216259,"gpt":0.2448031406450065,"spread":0.2297346681028439,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003682567,0.0003269042,0.0005833997,0.0007508072,0.0002350121,0.0004007767,0.000184741,0.0003380558,0.0009970545],"category_scores_gemma":[0.0003061106,0.0001738411,0.0001521872,0.0005308834,0.0003160425,0.0002648838,0.0003312726,0.0004375781,0.000290962],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004980122,"about_ca_system_score_gemma":0.0003118903,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004035435,"about_ca_topic_score_gemma":0.0004408775,"domain_scores_codex":[0.9998504,0.00003183761,0.00001337384,0.00003395346,0.00005111851,0.00001935719],"domain_scores_gemma":[0.9999071,0.00001188633,0.00003937876,0.000005580501,0.00002130306,0.00001471758],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001063216,0.0001010605,0.01060889,0.0002915033,0.0000355834,0.0001371113,0.00004642309,0.0003213293,0.9488646,0.000293826,0.0004370895,0.03779933],"study_design_scores_gemma":[0.0001045451,0.001922435,0.1230513,0.0000622263,0.0001616818,0.001901591,0.0001664061,0.004558076,0.8525697,0.0009731865,0.01450106,0.00002773926],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9758382,0.01650944,0.004447265,0.0005287199,0.0000394932,0.00008003107,0.0005849863,0.0001565881,0.001815259],"genre_scores_gemma":[0.9893216,0.002871461,0.005840053,0.0001266056,0.00002371588,0.00007581442,0.00059509,0.00001346014,0.00113216],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009970545,"threshold_uncertainty_score":0.003613353,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2054103222","doi":"10.1016/j.stem.2012.12.011","title":"A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition","year":2013,"lang":"en","type":"article","venue":"Cell stem cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":195,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Canada's Michael Smith Genome Sciences Centre; Ontario Institute for Cancer Research; BC Cancer Agency","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; Ontario Ministry of Research and Innovation; University of California, San Diego; Canadian Institutes of Health Research; Ontario Genomics Institute; China Scholarship Council; Genome Canada; National Institutes of Health; Ontario Genomics; National Cancer Institute; Government of Canada; California Institute for Regenerative Medicine","keywords":"Biology; Stem cell; Tyrosine-kinase inhibitor; Leukemia; Bone marrow; Cancer research; Tyrosine kinase; Immunology; Cell biology; Signal transduction; Cancer; Genetics","authors":[{"name":"Daniel Goff","is_ca":false},{"name":"Angela C. Court","is_ca":false},{"name":"Anil Sadarangani","is_ca":false},{"name":"Hye-Jung E. Chun","is_ca":true},{"name":"Christian Barrett","is_ca":false},{"name":"Maryla Krajewska","is_ca":false},{"name":"Heather Leu","is_ca":false},{"name":"Janine M. Low-Marchelli","is_ca":false},{"name":"Wenxue Ma","is_ca":false},{"name":"Alice Shih","is_ca":false},{"name":"Jun Wei","is_ca":false},{"name":"Dayong Zhai","is_ca":false},{"name":"Ifat Geron","is_ca":false},{"name":"Minya Pu","is_ca":false},{"name":"Lei Bao","is_ca":false},{"name":"Ryan Chuang","is_ca":false},{"name":"Larisa Balaian","is_ca":false},{"name":"Jason Gotlib","is_ca":false},{"name":"Mark D. Minden","is_ca":true},{"name":"Giovanni Martinelli","is_ca":false},{"name":"Jessica M. Rusert","is_ca":false},{"name":"Kim-Hien T. Dao","is_ca":false},{"name":"Kamran Shazand","is_ca":true},{"name":"Peggy Wentworth","is_ca":false},{"name":"Kristen M. Smith","is_ca":false},{"name":"Christina Jamieson","is_ca":false},{"name":"Sheldon Morris","is_ca":false},{"name":"Karen Messer","is_ca":false},{"name":"Lawrence S.B. Goldstein","is_ca":false},{"name":"Thomas J. Hudson","is_ca":true},{"name":"Marco A. Marra","is_ca":true},{"name":"Kelly A. Frazer","is_ca":true},{"name":"Maurizio Pellecchia","is_ca":false},{"name":"John C. Reed","is_ca":false},{"name":"Catriona Jamieson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01464464361081714,"gpt":0.234219884548629,"spread":0.2195752409378119,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000179654,0.0004144062,0.0004159794,0.00034766,0.0002210283,0.0004516045,0.0003040029,0.0002831206,0.002556616],"category_scores_gemma":[0.0001171047,0.000161298,0.0002171341,0.0003236996,0.0002581875,0.0002774524,0.0001859619,0.0009422007,0.0004073671],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002880316,"about_ca_system_score_gemma":0.0003079365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006827065,"about_ca_topic_score_gemma":0.001301047,"domain_scores_codex":[0.9998385,0.00002130501,0.00001665561,0.00003208642,0.00004470061,0.00004667611],"domain_scores_gemma":[0.9999158,0.00002082572,0.00001598596,0.00001280765,0.000007463942,0.00002705395],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0006032383,0.0002025887,0.0002256106,0.00003068361,0.00001662575,0.00006646262,0.00002437547,0.0002187707,0.9935482,0.000446775,0.0003099206,0.00430688],"study_design_scores_gemma":[0.0001332648,0.000619731,0.001348108,0.000003219708,0.00002314995,0.0002757833,0.00003136418,0.001217575,0.9927568,0.00008648173,0.003499533,0.00000490324],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909742,0.001340184,0.002691379,0.0002148339,0.00009974993,0.00007182238,0.000834678,0.0002890197,0.003484086],"genre_scores_gemma":[0.9956605,0.0005280119,0.001191078,0.00004928265,0.00001107906,0.0000373053,0.0006990253,0.00002528267,0.001798492],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002556616,"threshold_uncertainty_score":0.00855273,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3194203975","doi":"10.1182/blood.2021012082","title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology; National Cancer Institute; National Institute for Health and Care Research","keywords":"Ponatinib; Medicine; Internal medicine; Clinical endpoint; Adverse effect; Myeloid leukemia; Cohort; Confidence interval; Oncology; Nilotinib; Clinical trial; Imatinib","authors":[{"name":"Jörge E. Cortes","is_ca":false},{"name":"Jane F. Apperley","is_ca":false},{"name":"Elza Lomaia","is_ca":false},{"name":"Beatriz Moiraghi","is_ca":false},{"name":"Maria Undurraga Sutton","is_ca":false},{"name":"Carolina Pavlovsky","is_ca":false},{"name":"Charles Chuah","is_ca":false},{"name":"Tomasz Sacha","is_ca":false},{"name":"Jeffrey H. Lipton","is_ca":true},{"name":"Charles A. Schiffer","is_ca":false},{"name":"James McCloskey","is_ca":false},{"name":"Andreas Hochhaus","is_ca":false},{"name":"Philippe Rousselot","is_ca":false},{"name":"Gianantonio Rosti","is_ca":false},{"name":"Hugues de Lavallade","is_ca":false},{"name":"Anna Turkina","is_ca":false},{"name":"Christine Rojas","is_ca":false},{"name":"Christopher Arthur","is_ca":false},{"name":"Lori J. Maness","is_ca":false},{"name":"Moshe Talpaz","is_ca":false},{"name":"Michael J. Mauro","is_ca":false},{"name":"Tracey Hall","is_ca":false},{"name":"Vickie Lu","is_ca":false},{"name":"Shouryadeep Srivastava","is_ca":false},{"name":"Michael Deininger","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08930478020376911,"gpt":0.4306504869785546,"spread":0.3413457067747855,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002205532,0.001750482,0.002362691,0.0003559563,0.0003773358,0.001189872,0.0008737323,0.001738287,0.006036934],"category_scores_gemma":[0.002252629,0.0006018265,0.001454635,0.0003911472,0.001032152,0.001658563,0.0004797753,0.00325052,0.001075561],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000773092,"about_ca_system_score_gemma":0.001085747,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004430567,"about_ca_topic_score_gemma":0.001162248,"domain_scores_codex":[0.9990728,0.0004891899,0.00004720743,0.000178726,0.0000968859,0.0001152585],"domain_scores_gemma":[0.9991885,0.0001647777,0.0001917175,0.00007947632,0.00006586268,0.000309637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9527262,0.01307924,0.001314979,0.0006403249,0.001072968,0.000107987,0.00008475176,0.0006462067,0.004034908,0.000292358,0.002207395,0.02379261],"study_design_scores_gemma":[0.955902,0.04063166,0.001590712,0.00001186792,0.0001547263,0.00006124029,0.00001254921,0.0003259302,0.0002293387,0.000185238,0.0008812574,0.0000133847],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831255,0.003196744,0.0008744268,0.001078732,0.0004938213,0.006119125,0.001874516,0.0001782429,0.003058743],"genre_scores_gemma":[0.9821416,0.002386767,0.001743754,0.001662474,0.0004658625,0.006403606,0.002090193,0.00003659261,0.003069198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006036934,"threshold_uncertainty_score":0.02019554,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2157501125","doi":"10.1182/blood-2011-10-385658","title":"Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":187,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Medical Research Council; Imperial Experimental Cancer Medicine Centre; University of Pennsylvania; China Scholarship Council; Cancer Institute, University of Pittsburgh; Cancer Research UK; Peking University; National Institutes of Health; Warszawski Uniwersytet Medyczny; National Cancer Institute; Uniwersytet Warszawski; Cancer Research Institute; Temple University","keywords":"Genome instability; Myeloid leukemia; Biology; Cancer research; Stem cell; Progenitor cell; Mitochondrial ROS; Haematopoiesis; Mitochondrion; Molecular biology; DNA damage; Cell biology; Genetics","authors":[{"name":"Margaret Nieborowska-Skorska","is_ca":false},{"name":"Piotr Kopiński","is_ca":false},{"name":"Regina Ray","is_ca":false},{"name":"Grażyna Hoser","is_ca":false},{"name":"Danielle Ngaba","is_ca":false},{"name":"Sylwia Flis","is_ca":false},{"name":"Kimberly Cramer","is_ca":false},{"name":"Mamatha M. Reddy","is_ca":false},{"name":"Mateusz Koptyra","is_ca":false},{"name":"Tyrone Penserga","is_ca":false},{"name":"Eliza Głodkowska‐Mrówka","is_ca":false},{"name":"Elisabeth Bolton","is_ca":false},{"name":"Tessa L. Holyoake","is_ca":false},{"name":"Connie J. Eaves","is_ca":true},{"name":"Sabine Cerny‐Reiterer","is_ca":false},{"name":"Peter Valent","is_ca":false},{"name":"Andreas Hochhaus","is_ca":false},{"name":"Timothy P. Hughes","is_ca":false},{"name":"Heiko van der Kuip","is_ca":false},{"name":"Martin Sattler","is_ca":false},{"name":"W Wiktor-Jędrzejczak","is_ca":false},{"name":"Christine Richardson","is_ca":false},{"name":"Adrienne M. Dorrance","is_ca":false},{"name":"Tomasz Stokłosa","is_ca":false},{"name":"David A. Williams","is_ca":false},{"name":"Tomasz Skórski","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.020180924643032,"gpt":0.2512487543760032,"spread":0.2310678297329712,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000965456,0.0002237754,0.000169819,0.0001541613,0.0001272169,0.0002128076,0.0001619321,0.0002430887,0.0007413882],"category_scores_gemma":[0.00008687494,0.0001175306,0.0001488048,0.0001135433,0.0001366418,0.0001175834,0.0001513521,0.0004850185,0.0001883018],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002317058,"about_ca_system_score_gemma":0.000127878,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000455253,"about_ca_topic_score_gemma":0.0003668245,"domain_scores_codex":[0.9998586,0.00001914468,0.00001610241,0.00002762066,0.00005156558,0.00002693969],"domain_scores_gemma":[0.9999162,0.00001126332,0.00002643638,0.00001323317,0.000007541297,0.00002527817],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00004535474,0.00001051638,0.0001594819,0.00001175365,0.000002011656,0.00004808954,0.00001440831,0.00002641387,0.9991935,0.00007275771,0.00001533751,0.0004002947],"study_design_scores_gemma":[0.00001644355,0.0002365455,0.007243859,0.000003081627,0.00001062427,0.0004881582,0.00003234364,0.0008982727,0.9892156,0.00005139681,0.001800198,0.000003716152],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974514,0.000446844,0.001298206,0.00003831412,0.000006994116,0.00002041727,0.0001539491,0.00003840063,0.000545448],"genre_scores_gemma":[0.9973924,0.0002534092,0.0008385227,0.00002902134,0.000004287593,0.00003158082,0.0003579838,0.000007170746,0.001085678],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0007413882,"threshold_uncertainty_score":0.002480209,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2162340188","doi":"10.1158/1078-0432.ccr-09-0145","title":"Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; Imatinib; Pharmacogenetics; Medicine; Clinical significance; Oncology; Gene; Bioinformatics; Immunology; Internal medicine; Biology; Genetics; Genotype","authors":[{"name":"Dong‐Hwan Kim","is_ca":false},{"name":"Lakshmi Sriharsha","is_ca":false},{"name":"Wei Xu","is_ca":false},{"name":"Suzanne Kamel‐Reid","is_ca":true},{"name":"Xiangdong Liu","is_ca":true},{"name":"Katherine Siminovitch","is_ca":true},{"name":"Hans A. Messner","is_ca":false},{"name":"Jeffrey H. Lipton","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1807922541795707,"gpt":0.5079772695143526,"spread":0.3271850153347819,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00170534,0.0004792929,0.0005025218,0.0006698089,0.0002399123,0.0003428425,0.0002652364,0.0005396674,0.00140456],"category_scores_gemma":[0.005827162,0.0001322239,0.0002852505,0.0005367344,0.0003589121,0.0002224253,0.0002503865,0.0004803066,0.0002142071],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000240276,"about_ca_system_score_gemma":0.0003115985,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005098598,"about_ca_topic_score_gemma":0.0007879933,"domain_scores_codex":[0.9987967,0.0007084194,0.00008839476,0.0002022579,0.0001447379,0.00005949072],"domain_scores_gemma":[0.9973711,0.00172297,0.0005362066,0.00009727553,0.000112311,0.0001600322],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00119924,0.0001094106,0.9800136,0.00002357754,0.0001591259,0.0001906556,0.00002880698,0.001179791,0.00220168,0.00006558806,0.0001519285,0.01467661],"study_design_scores_gemma":[0.0002995953,0.001237686,0.9766759,0.00002147605,0.0003306173,0.001651144,0.00006970793,0.01559124,0.002509363,0.0007878687,0.0008060411,0.00001930222],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981052,0.0003844551,0.0007596753,0.0002374639,0.000009521781,0.00001750662,0.0001298602,0.000006997646,0.0003493069],"genre_scores_gemma":[0.999148,0.00003559212,0.0006030248,0.00004343129,0.00001665886,0.00001240902,0.00007142821,0.000001105077,0.00006821412],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00170534,"threshold_uncertainty_score":0.009018779,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2067382049","doi":"10.1038/onc.2010.67","title":"Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprograming","year":2010,"lang":"en","type":"article","venue":"Oncogene","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Biology; Imatinib mesylate; Cancer research; Transketolase; Imatinib; Myeloid leukemia; Biochemistry; Enzyme","authors":[{"name":"Fanyu Zhao","is_ca":false},{"name":"Anthony Mancuso","is_ca":false},{"name":"Thi Bui","is_ca":false},{"name":"Xiangmin Tong","is_ca":false},{"name":"Joshua J. Gruber","is_ca":false},{"name":"Cezary Swider","is_ca":false},{"name":"P V Sanchez","is_ca":false},{"name":"Julian J. Lum","is_ca":true},{"name":"Nadia Yasmina Ben Sayed","is_ca":false},{"name":"J V Melo","is_ca":false},{"name":"Alexander E. Perl","is_ca":false},{"name":"Martin Carroll","is_ca":false},{"name":"S.W. Tuttle","is_ca":false},{"name":"Craig B. Thompson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0199216976062795,"gpt":0.2846204596258328,"spread":0.2646987620195533,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001313866,0.000174111,0.0001798741,0.0002118084,0.0001661438,0.0002936465,0.0001126774,0.00019416,0.003077293],"category_scores_gemma":[0.0001485754,0.0001120569,0.0001924085,0.0001345102,0.0001675166,0.000169529,0.0002070317,0.0004041891,0.0004607956],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002811272,"about_ca_system_score_gemma":0.00009734014,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001773136,"about_ca_topic_score_gemma":0.0003318555,"domain_scores_codex":[0.9998872,0.00002147246,0.000008055458,0.00001619023,0.00002590651,0.0000411264],"domain_scores_gemma":[0.9999411,0.000008317259,0.0000252162,0.000007453297,0.000005868695,0.00001201335],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004286976,0.00006583297,0.001231094,0.0000359588,0.00001200386,0.000283476,0.000009287899,0.0001151993,0.9918411,0.0004748009,0.0004499605,0.005052523],"study_design_scores_gemma":[0.00009187585,0.0005891272,0.0749266,0.00001293322,0.00003818274,0.00355911,0.00007561706,0.002164689,0.9046864,0.0005544872,0.0132881,0.00001279264],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876398,0.003033712,0.002164769,0.0006768623,0.00006300058,0.00005576467,0.0006151117,0.0001527925,0.005598119],"genre_scores_gemma":[0.9974009,0.0004901022,0.0004423426,0.0000655574,0.00001140462,0.00002164634,0.000354687,0.000008828339,0.001204574],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003077293,"threshold_uncertainty_score":0.01029462,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2052054991","doi":"10.1182/blood-2012-02-410688","title":"A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"Canadian Cancer Society Research Institute; Ariad Pharmaceuticals; National Cancer Institute; National Institutes of Health; Pfizer; Oregon Health and Science University; Bristol-Myers Squibb","keywords":"Dasatinib; Medicine; Nilotinib; Imatinib; Internal medicine; Myeloid leukemia; Imatinib mesylate; Gastroenterology; Randomized controlled trial; Tyrosine-kinase inhibitor; Immunology; Cancer","authors":[{"name":"Jerald P. Radich","is_ca":false},{"name":"Kenneth J. Kopecky","is_ca":false},{"name":"Frederick R. Appelbaum","is_ca":false},{"name":"Suzanne Kamel‐Reid","is_ca":false},{"name":"Wendy Stock","is_ca":false},{"name":"Greg Malnassy","is_ca":false},{"name":"Elisabeth Paietta","is_ca":false},{"name":"Martha Wadleigh","is_ca":false},{"name":"Richard A. Larson","is_ca":false},{"name":"Peter D. Emanuel","is_ca":false},{"name":"Martin S. Tallman","is_ca":false},{"name":"Jeff H. Lipton","is_ca":true},{"name":"A. Robert Turner","is_ca":false},{"name":"Michael W. Deininger","is_ca":false},{"name":"Brian Druker","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02894547002878551,"gpt":0.3226977424825182,"spread":0.2937522724537327,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001330045,0.001220403,0.002011003,0.0003907787,0.0003459797,0.0008970517,0.0007286244,0.001286209,0.006558971],"category_scores_gemma":[0.001814787,0.0004984354,0.001151587,0.0003654076,0.001132903,0.000857651,0.0004784804,0.002427251,0.0008241566],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006655139,"about_ca_system_score_gemma":0.0008153901,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006528595,"about_ca_topic_score_gemma":0.001667073,"domain_scores_codex":[0.9993469,0.0004070537,0.00003935209,0.00008724549,0.0000404356,0.00007906162],"domain_scores_gemma":[0.9989748,0.0003063025,0.0002494198,0.00006637568,0.0000417314,0.0003614416],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9841803,0.002985322,0.0003270121,0.0002627826,0.000460226,0.00002647597,0.0000247177,0.000258749,0.001641133,0.0001345235,0.0006485339,0.009050149],"study_design_scores_gemma":[0.9680511,0.02989931,0.0008186634,0.00001307378,0.0001524153,0.00002157998,0.00001224702,0.0002460623,0.0001815359,0.0001293344,0.0004667634,0.000007945814],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882541,0.002884437,0.0005019749,0.0009842691,0.0006343245,0.003153417,0.00100772,0.00009826302,0.002481508],"genre_scores_gemma":[0.9864489,0.001718351,0.00122641,0.00141581,0.0004101116,0.003588214,0.001191791,0.00001861551,0.00398172],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006558971,"threshold_uncertainty_score":0.02194196,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4366822278","doi":"10.1038/s41408-023-00823-9","title":"Management of chronic myeloid leukemia in 2023 – common ground and common sense","year":2023,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bosutinib; Dasatinib; Nilotinib; Ponatinib; Medicine; Imatinib; Oncology; Imatinib mesylate; Internal medicine; Myeloid leukemia; Intensive care medicine","authors":[{"name":"Jayastu Senapati","is_ca":false},{"name":"Koji Sasaki","is_ca":false},{"name":"Ghayas C. Issa","is_ca":false},{"name":"Jeffrey H. Lipton","is_ca":true},{"name":"Jerald P. Radich","is_ca":false},{"name":"Elias Jabbour","is_ca":false},{"name":"Hagop M. Kantarjian","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04700418793668781,"gpt":0.3555606265684206,"spread":0.3085564386317328,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004061399,0.000341123,0.0005612032,0.0008463688,0.001807552,0.003918479,0.001207245,0.002748878,0.003218084],"category_scores_gemma":[0.008193984,0.0001746234,0.0005413128,0.001043875,0.002512718,0.003588331,0.004423512,0.003489919,0.001181889],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003229313,"about_ca_system_score_gemma":0.004442662,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002265425,"about_ca_topic_score_gemma":0.004057747,"domain_scores_codex":[0.9962174,0.001614081,0.0005333839,0.0002462022,0.001017805,0.0003712309],"domain_scores_gemma":[0.99754,0.0003349009,0.0004573056,0.0001570288,0.0006795735,0.0008311155],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002482857,0.0001661611,0.007109984,0.001455785,0.00007122675,0.007881095,0.003714132,0.0004902028,0.001467642,0.04279488,0.261815,0.6727857],"study_design_scores_gemma":[0.00004153242,0.0002116133,0.004264587,0.002201217,0.00002573635,0.01460473,0.002649061,0.0003322605,0.0002255747,0.03148539,0.9439031,0.00005509487],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.02976488,0.2414895,0.01499168,0.5996916,0.02165437,0.0002812821,0.0002654273,0.0002645444,0.09159664],"genre_scores_gemma":[0.406216,0.208379,0.02415665,0.2634682,0.06007977,0.0004312126,0.0009488387,0.0002352122,0.03608501],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.004061399,"threshold_uncertainty_score":0.02343047,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2128816533","doi":"10.3324/haematol.2009.017178","title":"Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis","year":2010,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"Medical Research Council; Cancer Research UK","keywords":"Mesenchymal stem cell; Myeloid leukemia; Cancer research; Imatinib; Stromal cell; Bone marrow; Progenitor cell; Leukemia; Imatinib mesylate; Stem cell; Immunology; Biology; Cell biology","authors":[{"name":"Fabrizio Vianello","is_ca":false},{"name":"Federica Villanova","is_ca":false},{"name":"Veronica Tisato","is_ca":false},{"name":"Stefania Lymperi","is_ca":false},{"name":"Ka-Kei Ho","is_ca":true},{"name":"Ana Cordeiro Gomes","is_ca":true},{"name":"David Marin","is_ca":false},{"name":"Dominique Bonnet","is_ca":false},{"name":"Jane F. Apperley","is_ca":false},{"name":"Eric W.‐F. Lam","is_ca":true},{"name":"Francesco Dazzi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01425844564813957,"gpt":0.2467644451454297,"spread":0.2325059994972901,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001110622,0.000276351,0.0002268067,0.000158109,0.0001013376,0.0002131593,0.0001118182,0.0001587909,0.001863005],"category_scores_gemma":[0.00006960065,0.00006970898,0.0001891052,0.0001243837,0.0001673826,0.0001048988,0.0001455056,0.0004065336,0.0004505898],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001449779,"about_ca_system_score_gemma":0.0002218139,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003346294,"about_ca_topic_score_gemma":0.000706092,"domain_scores_codex":[0.9998655,0.00002004714,0.00001516419,0.00001675163,0.00004798761,0.00003453452],"domain_scores_gemma":[0.9999317,0.000009647887,0.00002245238,0.000009232446,0.000008122244,0.00001891882],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002231301,0.00007168767,0.0004237359,0.00006322242,0.00000858822,0.00004690027,0.00001767557,0.00005680786,0.9963866,0.0001118287,0.00008895915,0.002500852],"study_design_scores_gemma":[0.00009442289,0.001383515,0.009416491,0.00001424413,0.00003589875,0.0005261734,0.00004394885,0.0006015474,0.9831791,0.00005935803,0.004641578,0.000003782618],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946374,0.002024958,0.001281479,0.0000981338,0.0000225595,0.00004429463,0.0004147408,0.000056108,0.001420246],"genre_scores_gemma":[0.995832,0.0008189061,0.0008750631,0.00005387039,0.00001324663,0.0000533369,0.0007695926,0.000007782007,0.001576138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001863005,"threshold_uncertainty_score":0.006232381,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1971880154","doi":"10.1182/blood-2010-06-291641","title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network","funders":"","keywords":"Philadelphia chromosome; Chronic myelogenous leukemia; ABL; Medicine; Biology; Leukemia; Immunology; Internal medicine; Genetics; Chromosomal translocation; Gene; Tyrosine kinase","authors":[{"name":"Helen White","is_ca":false},{"name":"Paul Matejtschuk","is_ca":false},{"name":"Peter Rigsby","is_ca":false},{"name":"Jean Gabert","is_ca":false},{"name":"Feng Lin","is_ca":false},{"name":"Y. Lynn Wang","is_ca":false},{"name":"Susan Branford","is_ca":false},{"name":"Martin C. Müller","is_ca":false},{"name":"Nathalie Beaufils","is_ca":false},{"name":"Emmanuel Beillard","is_ca":false},{"name":"Dolors Colomer","is_ca":false},{"name":"Dana Dvořáková","is_ca":false},{"name":"Hans Ehrencrona","is_ca":false},{"name":"Hyun‐Gyung Goh","is_ca":false},{"name":"Hakim El Housni","is_ca":false},{"name":"Dan Jones","is_ca":false},{"name":"Veli Kairisto","is_ca":false},{"name":"Suzanne Kamel‐Reid","is_ca":true},{"name":"Dong‐Wook Kim","is_ca":false},{"name":"Stephen E. Langabeer","is_ca":false},{"name":"Edmond S.K.","is_ca":false},{"name":"Richard D. Press","is_ca":false},{"name":"G. Romeo","is_ca":false},{"name":"Lihui Wang","is_ca":false},{"name":"Katerina Zoi","is_ca":false},{"name":"Timothy P. Hughes","is_ca":false},{"name":"Giuseppe Saglio","is_ca":false},{"name":"Andreas Hochhaus","is_ca":false},{"name":"John M. Goldman","is_ca":false},{"name":"Paul Metcalfe","is_ca":false},{"name":"Nicholas C.P. Cross","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02817571188612836,"gpt":0.2829879936704769,"spread":0.2548122817843486,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01929949,0.001098005,0.001293702,0.005177838,0.001336011,0.001825256,0.002167111,0.001630795,0.002581968],"category_scores_gemma":[0.01432526,0.0006196721,0.001188456,0.002861557,0.001516854,0.0007456935,0.0009534232,0.002046851,0.002373895],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001269089,"about_ca_system_score_gemma":0.004155009,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002957267,"about_ca_topic_score_gemma":0.004515038,"domain_scores_codex":[0.9858702,0.006965464,0.001400745,0.001274165,0.003917872,0.0005714308],"domain_scores_gemma":[0.9844474,0.002403811,0.001557879,0.002654169,0.00851702,0.0004197489],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001471518,0.00103164,0.03002756,0.00105794,0.000144856,0.0005534596,0.001057596,0.003086119,0.6295336,0.01059572,0.0163271,0.305113],"study_design_scores_gemma":[0.0002655134,0.00395189,0.0699731,0.0006098436,0.0004289526,0.002007274,0.0004614657,0.00586623,0.6040235,0.00394181,0.3082831,0.0001872881],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"methods","genre_gemma":"methods","genre_scores_codex":[0.2034182,0.00914199,0.7116661,0.004554232,0.00247285,0.006882035,0.01315386,0.002425011,0.04628563],"genre_scores_gemma":[0.141119,0.002620483,0.8223273,0.001051515,0.000352856,0.004705231,0.01806076,0.0003943201,0.009368488],"genre_candidate":"methods","genre_consensus":"methods","teacher_disagreement_score":0.01929949,"threshold_uncertainty_score":0.1020667,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2151724015","doi":"10.1016/j.cell.2011.08.046","title":"Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis","year":2011,"lang":"en","type":"article","venue":"Cell","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Basic Energy Sciences; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Austrian Science Fund; National Center for Research Resources; National Institute of General Medical Sciences; Österreichischen Akademie der Wissenschaften; University of Chicago; European Molecular Biology Organization; U.S. Department of Energy","keywords":"Biology; Interface (matter); Cell biology; ABL; Cancer research; Kinase; Tyrosine kinase; Signal transduction; Genetics; Computational biology; Biochemistry","authors":[{"name":"Florian Grebien","is_ca":false},{"name":"Oliver Hantschel","is_ca":false},{"name":"John Wojcik","is_ca":false},{"name":"Ines Kaupe","is_ca":false},{"name":"Boris Kovačic","is_ca":false},{"name":"Arkadiusz M. Wyrzucki","is_ca":false},{"name":"Gerald Gish","is_ca":true},{"name":"Sabine Cerny‐Reiterer","is_ca":false},{"name":"Akiko Koide","is_ca":false},{"name":"Hartmut Beug","is_ca":false},{"name":"Tony Pawson","is_ca":true},{"name":"Peter Valent","is_ca":false},{"name":"Shohei Koide","is_ca":false},{"name":"Giulio Superti‐Furga","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02668374775510418,"gpt":0.2497793741398237,"spread":0.2230956263847196,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001601452,0.0002553965,0.0002722545,0.0002335452,0.000260932,0.0003726762,0.0002726571,0.0003504642,0.003674889],"category_scores_gemma":[0.0001000157,0.000107767,0.0001496612,0.0001819161,0.0002512208,0.0002628691,0.0002532872,0.0009135808,0.0006615329],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003212457,"about_ca_system_score_gemma":0.0002637641,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003941117,"about_ca_topic_score_gemma":0.001341496,"domain_scores_codex":[0.9999094,0.00001105064,0.000004511715,0.000008659333,0.00002553702,0.00004087698],"domain_scores_gemma":[0.9999733,0.000004873905,0.000006097339,0.000003674731,0.000002450601,0.000009549671],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001927724,0.0008148394,0.000827055,0.0001823944,0.0000563072,0.0001572202,0.000050957,0.001215151,0.9517282,0.003203796,0.00255687,0.03727957],"study_design_scores_gemma":[0.001190114,0.003491074,0.008827058,0.00002348603,0.0000989028,0.0007856811,0.00009707628,0.003814847,0.9458836,0.001183216,0.0345857,0.00001910889],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830582,0.004754114,0.001602327,0.0007358812,0.0001253538,0.00006710103,0.0003197236,0.0001487106,0.009188495],"genre_scores_gemma":[0.9947672,0.001472532,0.0005304982,0.0001091594,0.00002840558,0.00003094384,0.0002593163,0.000008594335,0.002793437],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003674889,"threshold_uncertainty_score":0.01229376,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2981763967","doi":"10.1080/10428194.2019.1675879","title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Dasatinib; Discontinuation; Medicine; Myeloid leukemia; Internal medicine; Imatinib; Tyrosine-kinase inhibitor; Adverse effect; Tyrosine kinase; Oncology; Gastroenterology; Cancer; Receptor","authors":[{"name":"Neil P. Shah","is_ca":false},{"name":"Valentín García‐Gutiérrez","is_ca":false},{"name":"Antonio Jiménez‐Velasco","is_ca":false},{"name":"Sarah Larson","is_ca":false},{"name":"Susanne Saußele","is_ca":false},{"name":"Delphine Réa","is_ca":false},{"name":"François‐Xavier Mahon","is_ca":false},{"name":"Moshe Levy","is_ca":false},{"name":"María Teresa Gómez‐Casares","is_ca":false},{"name":"Fabrizio Pane","is_ca":false},{"name":"Franck‐Emmanuel Nicolini","is_ca":false},{"name":"Michael J. Mauro","is_ca":false},{"name":"Oumar Sy","is_ca":false},{"name":"Patricia Martin‐Regueira","is_ca":false},{"name":"Jeffrey H. Lipton","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.005489341495418336,"gpt":0.237756561886154,"spread":0.2322672203907357,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00153657,0.0005771222,0.001042827,0.0001877734,0.0002286278,0.0006080765,0.0002859661,0.0005330802,0.001296672],"category_scores_gemma":[0.001132303,0.0002348746,0.0008969594,0.0004062604,0.0003423145,0.0005052863,0.0003262992,0.0009536144,0.0002977134],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003129728,"about_ca_system_score_gemma":0.0005207408,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005331036,"about_ca_topic_score_gemma":0.001337414,"domain_scores_codex":[0.9994612,0.000294741,0.00004158212,0.00005743178,0.00007390917,0.00007113024],"domain_scores_gemma":[0.9992998,0.000178562,0.0002283625,0.000073738,0.00004101978,0.0001786235],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5831775,0.007433548,0.244399,0.00166172,0.005975209,0.0006843822,0.0004878002,0.001592152,0.01781003,0.000455152,0.004571265,0.1317523],"study_design_scores_gemma":[0.3767548,0.1565838,0.4401156,0.0001349818,0.003000732,0.001420417,0.0002578916,0.001486167,0.002732831,0.0005792383,0.0168581,0.00007537417],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953592,0.002670515,0.0001618125,0.0001498516,0.00003504213,0.0001569172,0.0006446019,0.000008958897,0.0008131965],"genre_scores_gemma":[0.9969104,0.00120619,0.0001530855,0.0002278103,0.00006974844,0.0001126547,0.0008661554,0.000003512562,0.0004503817],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00153657,"threshold_uncertainty_score":0.008126199,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2075548587","doi":"10.1182/blood.v97.3.720","title":"Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3","year":2001,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Biology; Myeloid leukemia; CD38; Interleukin 3; Progenitor cell; CD34; Leukemia; Cancer research; Population; Myeloid; Molecular biology; Growth factor; ABL; Immunology; Stem cell; Cell biology; T cell; Interleukin 21; Signal transduction; Immune system; Tyrosine kinase; Medicine; Receptor; Genetics","authors":[{"name":"Tessa L. Holyoake","is_ca":true},{"name":"Xiaoyan Jiang","is_ca":true},{"name":"Heather G. Jørgensen","is_ca":true},{"name":"Susan M. Graham","is_ca":true},{"name":"Michael J. Alcorn","is_ca":true},{"name":"Chris Laird","is_ca":true},{"name":"Allen Eaves","is_ca":true},{"name":"Connie J. Eaves","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.006904935077660119,"gpt":0.2076230744175077,"spread":0.2007181393398476,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001372668,0.0002133724,0.0003272609,0.0003574327,0.0001882571,0.0003408039,0.0001349109,0.0001506882,0.001832231],"category_scores_gemma":[0.0003194694,0.0001235585,0.0001380945,0.0002622193,0.0001549982,0.0001463079,0.0002336978,0.0003751956,0.0006082325],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001389565,"about_ca_system_score_gemma":0.000141401,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003300045,"about_ca_topic_score_gemma":0.0003581132,"domain_scores_codex":[0.9998904,0.00002021382,0.00001348325,0.0000212936,0.00002925719,0.00002531388],"domain_scores_gemma":[0.9998103,0.00005558363,0.00002554287,0.00002886596,0.00001498688,0.00006472204],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0007780503,0.00009742273,0.01663622,0.00005344988,0.00001493899,0.0005807773,0.0002914239,0.0001187336,0.9715739,0.0002043881,0.0002624703,0.009388229],"study_design_scores_gemma":[0.0003741883,0.005270483,0.2815627,0.00006183354,0.000147156,0.01766217,0.0003477598,0.002684965,0.6660384,0.0007160248,0.02509559,0.00003869813],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954637,0.001482927,0.00106271,0.00004020828,0.00001074842,0.00004820587,0.0003789627,0.0000717346,0.001440758],"genre_scores_gemma":[0.9959909,0.0004681561,0.0008509518,0.00006265062,0.00002118816,0.00005746957,0.001654956,0.00001720004,0.000876461],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001832231,"threshold_uncertainty_score":0.006129384,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2066023838","doi":"10.1016/j.exphem.2003.10.010","title":"SCL: From the origin of hematopoiesis to stem cells and leukemia","year":2004,"lang":"en","type":"review","venue":"Experimental Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Haematopoiesis; Transcription factor; Biology; Stem cell; Regulator; Hematopoietic stem cell; Leukemia; Cell biology; Transcription (linguistics); Genetics; Gene; Lineage (genetic); Computational biology; Cancer research","authors":[{"name":"Éric Lécuyer","is_ca":true},{"name":"Trang Hoang","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04608980461120263,"gpt":0.3493217444556989,"spread":0.3032319398444963,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007427563,0.0009783477,0.001876594,0.002510838,0.0003944767,0.001307445,0.001308402,0.001537334,0.003455556],"category_scores_gemma":[0.0007862265,0.0003027958,0.0004218272,0.003119391,0.001025581,0.001554482,0.0007303252,0.002701301,0.002461713],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000949945,"about_ca_system_score_gemma":0.001445343,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001662788,"about_ca_topic_score_gemma":0.003535352,"domain_scores_codex":[0.9998236,0.00003273248,0.00002344658,0.00003087329,0.00007257648,0.00001671112],"domain_scores_gemma":[0.9995863,0.000198277,0.0000544229,0.0000143415,0.0001057271,0.0000409637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000128943,0.00008498893,0.0001493282,0.01136242,0.00006749434,0.0002030331,0.00004685632,0.0003181822,0.001787031,0.004520371,0.03659572,0.9447356],"study_design_scores_gemma":[0.00003423241,0.00006421277,0.0004310016,0.001941181,0.00006221851,0.0007574821,0.00004463118,0.00004452863,0.0005226283,0.001885414,0.9942,0.00001233564],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005444178,0.9987018,0.00008609157,0.0002645485,0.0001968006,0.000002936072,0.00001031347,0.000004849572,0.0006781786],"genre_scores_gemma":[0.0003594899,0.9985239,0.0001277302,0.0002451969,0.0001910211,0.000004281892,0.00001993668,9.802906e-7,0.000527488],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003455556,"threshold_uncertainty_score":0.01155996,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2950655888","doi":"10.1038/s41375-019-0512-y","title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","year":2019,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research; Howard Hughes Medical Institute","keywords":"Myeloid leukemia; Disease; Medicine; Drug resistance; Cancer; Bioinformatics; Intensive care medicine; Oncology; Internal medicine; Biology; Genetics","authors":[{"name":"Susan Branford","is_ca":false},{"name":"Dennis Dong Hwan Kim","is_ca":true},{"name":"Jane F. Apperley","is_ca":false},{"name":"Christopher A. Eide","is_ca":false},{"name":"Satu Mustjoki","is_ca":false},{"name":"S. Tiong Ong","is_ca":false},{"name":"Georgios Nteliopoulos","is_ca":false},{"name":"Thomas Ernst","is_ca":false},{"name":"Charles Chuah","is_ca":false},{"name":"Carlo Gambacorti‐Passerini","is_ca":false},{"name":"Michael J. Mauro","is_ca":false},{"name":"Brian Druker","is_ca":false},{"name":"Dong‐Wook Kim","is_ca":true},{"name":"François‐Xavier Mahon","is_ca":false},{"name":"Jörge E. Cortes","is_ca":false},{"name":"Jerry Radich","is_ca":false},{"name":"Andreas Hochhaus","is_ca":false},{"name":"Timothy P. Hughes","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05262389046321067,"gpt":0.3617774958511126,"spread":0.3091536053879019,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00189906,0.0006672748,0.002043261,0.001586674,0.0002383071,0.001413339,0.0009530994,0.001459904,0.00389755],"category_scores_gemma":[0.004096179,0.0002703912,0.001124534,0.001384197,0.0006105667,0.001389733,0.0008698368,0.003131179,0.0008189509],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000972047,"about_ca_system_score_gemma":0.002013596,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002322721,"about_ca_topic_score_gemma":0.004198974,"domain_scores_codex":[0.9994668,0.000205574,0.00008039569,0.00007401074,0.0001418285,0.00003137008],"domain_scores_gemma":[0.9977232,0.001755227,0.0001700163,0.00003652978,0.0002651339,0.00004997212],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009173251,0.00004635465,0.0002727856,0.02307157,0.0003342166,0.00009099043,0.00004248917,0.0005961803,0.0003176111,0.008738261,0.02099994,0.9453979],"study_design_scores_gemma":[0.00009196537,0.0001557502,0.001544098,0.03145112,0.001061222,0.0007051321,0.0001169863,0.000387079,0.0003011773,0.01595249,0.9481847,0.00004820891],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003348427,0.9986952,0.0001428571,0.0006282289,0.0001271504,0.000002639016,0.00001687977,0.000003508791,0.0003501174],"genre_scores_gemma":[0.0006623019,0.9980739,0.0002911631,0.0005870863,0.0002110715,0.000005134192,0.00002337176,0.00000108007,0.0001449438],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00389755,"threshold_uncertainty_score":0.01303858,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2169508471","doi":"10.1200/jco.2002.06.077","title":"Long-Term Medical Outcomes and Quality-of-Life Assessment of Patients With Chronic Myeloid Leukemia Followed at Least 10 Years After Allogeneic Bone Marrow Transplantation","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Population; Myeloid leukemia; Transplantation; Internal medicine; Bone marrow; Leukemia; Surgery","authors":[{"name":"Thomas Kiss","is_ca":true},{"name":"Mohamed Abdolell","is_ca":true},{"name":"N Jamal","is_ca":true},{"name":"Mark D. Minden","is_ca":true},{"name":"Jeffrey H. Lipton","is_ca":true},{"name":"Hans A. Messner","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06492735229229302,"gpt":0.408487949971739,"spread":0.343560597679446,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006129252,0.000237771,0.0003236336,0.000579343,0.000396862,0.0004210667,0.0001701181,0.0003522255,0.0006977873],"category_scores_gemma":[0.002019454,0.00009258405,0.0003475764,0.0004404473,0.0002586806,0.0004026854,0.000429956,0.000390969,0.000124051],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002455595,"about_ca_system_score_gemma":0.0002397776,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009842728,"about_ca_topic_score_gemma":0.001437746,"domain_scores_codex":[0.9997032,0.00008037852,0.00004198874,0.00004062507,0.00006242917,0.00007133587],"domain_scores_gemma":[0.9984591,0.0001850369,0.0007955199,0.00004000016,0.0001358835,0.0003843894],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001223539,0.00003667408,0.9979609,0.000008030192,0.00003024624,0.00009839928,0.00005243344,0.00005081437,0.000219784,0.000003702947,0.00003540598,0.001381209],"study_design_scores_gemma":[0.000009826445,0.0004094413,0.9984634,0.000006763995,0.00002511414,0.0006599788,0.00009578228,0.0001313167,0.00008005543,0.000008327729,0.0001060951,0.00000390254],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9996209,0.0001527305,0.00002738209,0.00001915963,0.000002426285,0.000003284486,0.00009095923,8.149871e-7,0.0000823474],"genre_scores_gemma":[0.999598,0.00004679184,0.0000336432,0.00001489978,0.000005570026,0.000004727603,0.0002561153,3.065554e-7,0.0000398684],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009842728,"threshold_uncertainty_score":0.003241539,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2029310284","doi":"10.1592/phco.24.16.1508.50958","title":"The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate","year":2004,"lang":"en","type":"article","venue":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Institute of General Medical Sciences","keywords":"Imatinib mesylate; Pharmacokinetics; Pharmacology; Mesylate; Medicine; Chemistry; Imatinib; Internal medicine","authors":[{"name":"Patrick F. Smith","is_ca":false},{"name":"Julie Bullock","is_ca":false},{"name":"Brent M. Booker","is_ca":false},{"name":"Curtis E. Haas","is_ca":false},{"name":"Charles S. Berenson","is_ca":false},{"name":"William J. Jusko","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01955758906830467,"gpt":0.3302328160462573,"spread":0.3106752269779526,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005380335,0.0003940373,0.0005489068,0.0001138133,0.0001079963,0.0002586707,0.0001287925,0.0003188775,0.001545313],"category_scores_gemma":[0.001386571,0.000207149,0.0002747301,0.0001034567,0.000442279,0.0002249824,0.0001164353,0.0004149446,0.0002031606],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002454675,"about_ca_system_score_gemma":0.0002433718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000369401,"about_ca_topic_score_gemma":0.0007661504,"domain_scores_codex":[0.9996246,0.0001549065,0.00002387019,0.00005871688,0.00009339026,0.00004452369],"domain_scores_gemma":[0.9993734,0.000256884,0.0002181906,0.00003361544,0.0000242821,0.00009376806],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.2157417,0.006655097,0.01583331,0.00066876,0.0006498644,0.0004214154,0.0001896046,0.001411524,0.648551,0.0001622951,0.0006244043,0.109091],"study_design_scores_gemma":[0.01965668,0.4215195,0.3107413,0.00004679752,0.0009225927,0.002224057,0.0001146565,0.005256925,0.2351898,0.0001914785,0.004072429,0.0000637921],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9989181,0.0005529535,0.0001425415,0.00003246446,0.00001333454,0.00002589725,0.00004309818,0.000006908359,0.000264687],"genre_scores_gemma":[0.9988484,0.0003335812,0.0002880599,0.00004435153,0.00002982464,0.00001881074,0.00008328499,0.000004860165,0.0003487658],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001545313,"threshold_uncertainty_score":0.00516957,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}